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ABSTRACT 
Hoa Bich Nguyen 
 
THE TUMOR SUPPRESSING ROLES OF TISSUE STRUCTURE IN CERVICAL CANCER 
DEVELOPMENT 
 
Cervical cancer is caused by the persistent infection of human papilloma virus (HPV) in 
the cervix epithelium. Although effective preventative care is available, the widespread nature of 
infection and the variety of HPV strains unprotected by HPV vaccines necessitate a better 
understanding of the disease for development of new therapies. A major tumor suppressing 
mechanism is the inhibition of cell division by tissue structure; however, the underlining 
molecular circuitry for this regulation remains unclear. Recently, the Yap transcriptional co-
activator has emerged as a key growth promoter that mediates contact growth arrest and limits 
organ size. Thus, we aimed to uncover upstream signals that connect tissue organization to Yap 
regulation in the inhibition of cervical cancer. Two events that disrupt tissue structure were 
examined including the loss of the tumor suppressor LKB1 and the expression of the viral 
oncogene HPV16-E6. We identified that Yap mediates cell growth regulation downstream of 
both LKB1 and E6. Restoration of LKB1 expression in HeLa cervical cancer cells, which lack 
this tumor suppressor, or shRNA knockdown of LKB1 in NTERT immortalized normal human 
dermal keratinocytes, demonstrated that LKB1 promotes Yap phosphorylation, nuclear exclusion, 
and proteasomal degradation. The ability of phosphorylation-defective Yap mutants to rescue 
LKB1 phenotypes, such as reduced cell proliferation and cell size, suggest that Yap inhibition 
contributes to LKB1 tumor suppressor function(s). Interestingly, LKB1’s suppression of Yap 
activity required neither the canonical Yap kinases, Lats1/2, nor metabolic downstream targets of 
LKB1, AMPK and mTORC1. Instead, the scaffolding protein NF2 was required for LKB1 to 
induce a specific actin cytoskeleton structure that associates with Yap suppression. Meanwhile, 
vii 
 
HPV16-E6 promoted Yap activation in all stages of keratinocyte differentiation. E6 activated the 
Rap1 small GTPase, which in turn promoted Yap activity. Since Rap1 does not mediate 
differentiation inhibition caused by E6, E6 may play a role in promoting cell growth through 
Rap1-Yap activation rather than preventing growth arrest through the disruption of 
differentiation. Altogether, the LKB1-NF2-Yap and E6-Rap1-Yap pathways represent two 
examples of a novel phenomenon, whereby the structure of a cell directly influences its gene 
expression and proliferation. 
 
 
 
Lawrence A. Quilliam, PhD, Chair 
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CHAPTER 1. INTRODUCTION  
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1.1. CERVICAL CANCER EPIDEMIOLOGY AND CAUSAL FACTORS 
 
Cervical cancer is responsible for 275,000 deaths every year making it the third most 
common cause of cancer-related death in women worldwide (1-3). Persistent infection by certain 
strains of the Human Papilloma Virus (HPV) has been shown to be the major cause of these 
cervical cancer cases. This discovery has led to very effective preventative treatments such as 
routine screening and HPV vaccines (3). Unfortunately, not all strains of HPV are blocked by 
these vaccinations and there is a lack of routine screening in many regions of the world. 
Therefore, cervical cancer remains a major health concern worldwide.  
Nearly 100 different types of papillomavirus have been identified, of which more than 35 
types of HPV have been isolated in neoplastic lesions of the anogenital tract (1). These viral 
infections can be sexually transmitted or occur from mother to child. Both men and women can 
be infected by HPV. However, women are more at risk for HPV-related cancers because estrogen 
may promote cancer development and the internal locations of cervical tumors hinder detection 
until late in the diseases development (1, 4). HPV infects undifferentiated basal cells of the 
epithelia, where its genome is maintained at a low copy number. As the cells become increasingly 
differentiated in the upper dermal layers, the viral genome is amplified and encapsulated virons 
are sloughed off in the dead squames (2). Some strains of HPV are associated with benign lesions 
or warts. These strains, including HPV 6 and HPV 11, are considered “low risk.” High risk strains 
include HPV 16, 18, 31, and 45. These strains have transforming potential and can replicate in 
more differentiated epithelial layers. Thus, these high risk strains are more effective at preventing 
the host cell from terminally differentiating or dying (5, 6). Consequently, the high risk strains 16 
and 18 account for over 70% of all cervical carcinomas (1). 
After infection by high risk HPV, cervical cancer begins with an asymptomatic stage 
where abnormal epithelial (skin) cells are confined to a lesion known as cervical intraepithelial 
neoplasia (CIN) in the epithelium of the cervix. This stage is followed by a transition stage 
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characterized by moderate to severe dysplasia, in which small clusters of neoplastic cells 
proliferate and may micro-invade the basement membrane. However, these dysplastic cells are 
still confined to the CIN lesion. If left untreated, the tumor progresses to the invasive stage where 
the tumor cells extend deep into the underlying stroma of the cervix (Figure 1-1). Ultimately, 
cancerous cells will invade into blood vessels and lymphatic channels allowing metastatic spread 
of these cells to other organs (1).  
Although high-risk HPV strains are detected in almost 100% of cervical cancer samples, 
cooperative mutations contribute significantly to the development of this disease (1, 2). Indeed, a 
great number of HPV infections are resolved spontaneously without developing into cervical 
cancer (4). Persistent viral infection causes host cells to have genomic instability that might lead 
to mutation in tumor suppressing genes. These cooperative mutations play important roles in the 
degree of malignancy and patient survival (Figure 1-1). An example of cooperative mutation is 
the loss of LKB1 tumor suppressor. Patients with cervical cancer that is deficient for LKB1 have 
a median survival of 13 months while survival associated with LKB1-wild type tumors is greater 
than 100 months (7). A different example, glucose transporter 1 is highly expressed while the 
differentiation promoter, Notch 1 is strongly suppressed in high-risk HPV lesions, cervical 
cancer, and metastatic cancer compared to preneoplastic lesions (8). Therefore, new therapeutic 
treatments will require a better understanding of the viral oncoproteins HPV-E6 and E7 as well as 
tumor suppressing mechanisms that were lost during this cancer progression. 
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1.2. NORMAL DIFFERENTIATION PROCESS AND CELL-CELL JUNCTIONS IN THE 
CREATION OF EPITHELIAL (SKIN) TISSUE 
 
 The formation of normal epithelial tissue structure not only protects the body from 
environmental insults it also serves to prevent the development of neoplastic growths. Breakdown 
in this tissue structure is associated with tumor growth, including cervical cancer. The epithelial 
structure consists of multiple cellular layers. The innermost layer of the epidermis is basal layer, 
followed by spinuous layer, granual layer, transitional layer, and cornified layer at the skin 
surface (Figure 1-2). These layers are made of several cell types including melanocytes, 
Langerhans (immune) cells, and the most abundant type, keratinocytes. Keratinocytes provide 
major structural components to the barrier layers of the skin (9). Keratinocytes first arise in the 
basal layer. Following cell division, most cells undergo a programmed process called 
differentiation as they migrate upward and away from the basal layer that retains the stem cells. 
As keratinocytes differentiate, they change both biochemically and morphologically. Matured 
keratinocytes contain two major cyto-structures called the intermediate filaments and the 
cornified envelope. The intermediate filaments are assembled from keratin monomers and the 
cornified envelope is assembled from involucrin and several membrane proteins (10). 
Keratinocytes with these cyto-structures attach to neighboring cells through adhesion proteins and 
lipids released from lamellar granules (Figure 1-2).  
 The differentiation process of keratinocytes is regulated both spatially and temporally by 
cell-cell adhesions and external stimuli such as vitamin A and calcium. Vitamin A drives 
differentiation upon being metabolized through various intermediates to retinoic acid, which 
binds to nuclear retinoic acid receptors. These receptors play an important role in modulating the 
transcriptions of genes that influence the differentiation process (11). Extracellular calcium level 
increases in the upper epithelial layers and this promotes the activation of proteins that mediate 
cell cohesion in the adherens junctions and tight junctions. Meanwhile, intracellular calcium 
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regulates the formation of desmosomal junctions and various calcium pump mutations lead to 
skin diseases such as Hailey-Hailey disease and Darier disease (12-14). Additionally, calcium 
activates transglutaminase, a protein at the interface between the living epidermal layers and the 
dead surface layer. This results in transglutaminase covalently attaching involucrin to membrane 
proteins for the formation of the cornified envelope surrounding the cells (10). 
 Depending on their differentiation stages, different types of cell junctions facilitate 
adhesion of keratinocytes to each other. Adherens and desmosomal junctions exist in the majority 
of skin layers, with the exception of the cornified layer. Tight junctions are formed at the granual 
layer just below the surface and specialized corneodesmosomal junctions are at the uppermost 
layer (Figure 1-2). Adherens junctions couple intercellular adhesion to the cytoskeleton therefore 
they relate a number of signaling cues important for cell shape, division, growth, and apoptosis. 
Adherens junctions are composed of strands of either the classical cadherin/catenin protein 
complexes or the nectin/afadin protein complexes. Classical cadherins are calcium-dependent cell 
adhesion molecules that interact with α and β-catenins via their cytoplasmic tail. Nectins are IgG-
like cell adhesion molecules that bind to afadin. Both of these receptor complexes bind to and 
regulate the actin cytoskeleton. In the skin, desmosomal junctions play the major role in cell 
cohesion. Desmosomal junctions are composed of the desmosomal cadherins, which are members 
of the cadherin superfamily. The extracellular ends of desmosomal cadherins interact with each 
other, while the intracellular ends bind to adaptor proteins to form desmosomal plaques that 
anchor to keratin filaments. Many different types of desmosomal cadherins are continuously 
recycled or replaced throughout the life cycle of the keratinocytes. This dynamic process allows 
for changes in the composition of proteins in the desmosomes, their sizes, and stability according 
to the cell’s stage of differentiation. Tight junctions form the barrier of the skin that regulates 
transcellular water, ions, and larger molecules. Tight junctions occur in both simple (single layer) 
epithelium and stratified (multi layers) epithelium where they separate the apical membrane 
domain from the basolateral part of the cell. The apical domain of the cell faces the lumen, 
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exterior environment while the basolateral part of the cell interacts with other cells or the cell-
extracellular matrix (ECM). As cells enter the granual layer of the skin, tight junction proteins 
including Claudins, Occluden, and Zona Occluden (ZO) are assembled to form the tight junction 
structure. It remains unclear what signals in the granual layer promote this assembly since many 
tight junction components are expressed throughout the epidermal layers. Ultimately, 
keratinocytes are terminally differentiated to become corneocytes and commit to an epidermal 
programmed cell death similar to apoptosis (15). This dead surface layer of the skin (cornified 
layer) is structurally relevant to the skin’s protective function. It consists of cells in cornified 
envelopes that are attached to each other by corneodesmosomal junction, which are static (unable 
to be recycled) desmosomal junctions. The corneodesmosomes are eventually degraded by 
adequate hydrolyses and corneocytes are sloughed off in dead squames (16).  
 The differentiation process allows keratinocytes to form various types of junctions. 
Conversely, the formation of cell junctions influences the differentiation process and the 
epithelial structure. These events are interconnected for the creation of a cohesive and flexible 
epithelium.  
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Figure 1-2.  The differentiation process is required for the formation of functional layers of the 
skin.   
 
Keratinocytes arise from the basal layer. As these cells proliferate and migrate upward, they undergo a 
programmed process where they differentiate into mature keratinocytes or corneocytes. Corneocytes 
have two major cyto-structures called the intermediate filaments and the cornified envelope. The 
intermediate filaments are assembled from keratin monomers and the cornified envelope is assembled 
from involucrin and several membrane proteins. Keratinocytes with these cyto-structures attach to 
neighboring cells through adhesion proteins and lipids released from the lamellar granules, forming a 
cohesive and flexible epithelium. 
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1.3. EPITHELIAL TISSUE STRUCTURE IS A MAJOR TUMOR SUPPRESSING 
MECHANISM 
 
The epidermis turns over at an incredibly fast rate of 14 days to maintain an adult’s skin. 
This equates to the creation of roughly 2 billion new epithelial cells each year (9). These cells 
often come in contact with cancer promoting agents such as UV light, free radicals, and chemical 
carcinogens. However, epithelial cancer is prevented in part by the tumor suppressing properties 
of the epithelial tissue structure.  
Epithelial cells stop growing as they differentiate and are compacted in the epidermal 
layers. This is a common property of all differentiated tissues in a multicellular animal. The 
control of proliferation in conjunction with the regulation of cell death governs the shape and size 
of an organ during embryonic development, maintains tissue homeostasis, and allow for rapid 
growth in wound healing. As a tissue’s structure increases in complexity, the regulation of growth 
and death become more intricate. The current perspective is that cancer cells arise upon defects in 
such regulation. For instance, the loss of E-cadheren and integrins, and hyper-activation of 
growth factor receptors such as ErbB2, TGF, and FGF receptors lead to disruption of tissue 
organization and the development of cancer (17, 18). Additionally, signaling pathways with 
important roles during embryonic development are often activated in cancers. This includes the 
JAK/STAT, Notch, MAPK/ERK, PI3K/AKT, NF-kB, Wnt and TGF-β pathways (19). 
Conversely, maintaining tissue homeostasis strongly inhibits cancer cell growth (20). 
Specifically, the skin structure suppresses the initiation of cancer by chemical carcinogens. This 
effect was discovered in the 1940s and is referred to as the “mutation/tumor suppressor” property 
of the skin (21, 22). A more recent study also found that epithelial tissue architecture provides 
resistance to c-myc induced cell growth, while disrupted structure cannot (23). Consistently, the 
loss of cell structure and differentiation is directly associated with cervical cancer. Indeed, 
physicians categorize tumor malignancy (also known as the grades of cervical intraepithelial 
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neoplasia (CIN)) by the degree of tissue structure disruption (Figure 1-1). The lowest risk of CIN 
progression to Squamous Cell Carcinoma (SCCA) is with CIN1, where undifferentiated cells and 
abnormal stratification (layer organization) are limited to the upper two-third of the epithelium. 
The highest risk is with CIN3, where abnormal cells occupy the full thickness of the epithelium 
and a complete loss of polarized tissue structure is observed (24).  
Inhibition of proliferation by cell-cell contact is also observed in cultured immortalized 
mammalian cells. Non-cancerous cells grow to confluence and stop proliferating as they come in 
contact with each other. This phenomenon is called cell-cell contact inhibition of cell division 
(also known as postconfluence inhibition). Mirroring in situ carcinoma, the tumorigenicity of a 
number of cell lines are inversely correlated with their sensitivity to growth inhibition by contact 
with other cells (25). Thus, contact inhibition is a common assay for the study of proliferative 
regulation using cultured cells. This has been further refined by the development of three 
dimensional (3D) cultures. In addition to cell-cell interaction available in 2D monolayer, 3D 
culture provides cell-extracellular matrix (ECM) interactions due to cell adhesion to a laminin-
rich matrix (Matrigel). Non-cancerous breast epithelial cells grow into acini in 3D culture. These 
acini represent a simple form of tissue structure. This culturing method confirmed that growth 
promoting pathways cause disturbance to the polarized structure, and the suppression of these 
signals restore acini architecture (17). 
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1.4. THE TRANSCRIPTIONAL CO-ACTIVATOR YAP REGULATES TISSUE 
HOMEOSTASIS 
 
The Hippo pathway has recently emerged as a key inhibitor of epithelial cell proliferation 
to regulate tissue homeostasis (26). First identified in Drosophila, the Hippo pathway is a kinase 
cascade involving the kinase Hippo that phosphorylates and activates Warts. Active Warts then 
phosphorylates and inhibits the transcriptional co-activator Yorkie through cytoplasmic retention. 
Thus, Yorkie cannot localize to the nucleus and promote the transcription of proliferative genes 
once the Hippo kinases are activated. This pathway is conserved in mammalian cells with many 
redundancies (Table 1-1). Mst1 and 2 (mammalian ortholog of Hippo) activate Lats1 and 2 
(Warts), which in turn suppresses Yap and Taz (Yorkie). In mammalian cell, Yap and Taz 
cooperate with transcription factors that are downstream of major developmental and cancer-
promoting pathways such as SMADs (TGFβ and BMP pathways), β-catenin (WNT pathway), 
and TEAD (27). Thus, the Hippo kinases Mst and Lats function to inhibit cancer growth (28-30). 
During the formation of apical-basal polarity in epithelial cell, mammalian Yap, or its fly 
ortholog Yorkie, is down-regulated through interaction with cell junction proteins, such as α-
catenin and the atypical cadherin, Fat, respectively (31, 32). Conversely, constitutive Yap 
expression induces epithelial-mesenchymal transition (EMT) in mammary cells grown in three-
dimensional culture (33), indicating its oncogenic potential. Consistently, many studies have 
implicated Hippo signaling with cancer development. For instance, Yap overexpression (34) or 
loss of upstream suppressors Mst, Salvador, or Merlin/NF2 (35) lead to hepatomegaly and liver 
carcinomas. Furthermore, multiple human cancers have elevated Yap protein and nuclear 
localization (36). 
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Table 1-1.  Drosophila members of the Hippo pathway and their mammalian orthologs. 
 
Core components of the Hippo pathway (Hpo-Wts-Yki) were first identified in Drosophila, their 
mammalian orthologs were later found to have similar functions. These components’ names are listed 
below. 
 
Type Human Fly 
Name Abbreviation Name Abbreviation 
Kinase 
Mammalian STE20-like 
protein kinase 
MST1/2 or 
STK3/4 Hippo Hpo 
Kinase Large tumor suppressor LATS1/2 Warts Wts 
Scaffold Salvador homolog 1 Sav1 or WW45 Salvador Sav 
Scaffold 
Mps One Binder kinase 
activator-like 1B Mob1 
Mob-as-tumor-
suppressor Mats 
transcriptional 
co-activator 
Yes tyrosine kinase-
associated protein Yap1/2 Yorkie Yki 
transcriptional 
co-activator 
WW domain containing 
transcription regulator 1    Taz or WWTR1     
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Since mammalian tissue structure is more complex, regulation of growth and death is also 
more intricate and fine-tuned in mammalian cells (Figure 1-3). The suppression of Yap is not an 
exception. Mass spectrometry analysis of Yap isolated from non-cancerous breast epithelial cells 
reveals 10 different phosphorylated serines. Guan’s lab reported that five of these sites can be 
phosphorylated by Lats1 and Lats2 (Warts orthologs), including the key phosphorylation of 
serine 127 (37). In disagreement with this report, Sudol reported that Akt is the kinase that 
phosphorylates Yap on this site (38). Nonetheless, both labs agree that this phosphorylation site 
allows for 14-3-3 binding and consequently nuclear exclusion of Yap. Additionally, Yap contains 
a Post-synaptic density, Discs large, Zonula occludens (PDZ)-binding domain at its C-terminus. 
This binding domain allows Yap binding to Zona Occluden 2 (ZO-2) and is required for the 
transportation of Yap into the nucleus (39). Aside from 14-3-3 and ZO-2 binding, the localization 
of Yap is also regulated by mechanical forces such as stress fibers and adhesion surfaces (40, 41). 
Meanwhile, the phosphorylation of Serine 381 by Lats 1 and 2 was shown to prime Yap for 
further phosphorylation by Casein Kinases δ and ε. This event creates a phosphodegron sequence 
for an E3 ligase, β-TRCP, to bind to Yap for ubiquitylation and proteasomal degradation (42). 
Double mutation of S127 and S381 stabilizes Yap and promotes oncogenic phenotypes, but 
neither mutation alone can induce cellular transformation (42). Thus, Yap is regulated both 
spatially (nuclear exclusion) and temporally (degradation).  
The signaling of Hippo kinases upstream of Yki is well worked out in Drosophila in 
contrast to events regulating Yap in mammals. The Drosophila membrane complex Fat-Lft-Dco 
translates extracellular stimuli to Expanded-Merlin-Kibra and nonconventional myosin Dachs. 
These proteins and complexes in turn promote the activation of Hippo kinases and Yorkie 
cytosolic retention. In contrast, the compositions of mammalian protein complexes that suppress 
Yap remain unclear. Controversy regarding Yap regulators in mammalian cells likely stems from 
redundant kinases, scaffolding proteins, and differential signals. In response to E-cadherin 
engagement, Lats is activated and Yap is suppressed; however, Mst 1 and 2 are not required for 
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Lats activation (43). Alternatively, in keratinocytes and in respond to mechanical forces, Yap is 
phosphorylated independent of Mst and Lats (32, 41). Whether these results suggest redundancy 
of Hippo kinases in certain mammalian systems will require further investigation. More 
importantly, no complex similar to the fly’s Fat-Lft-Dco or Dachs has been identified. The hint 
that Dco is closely related to Casein Kinase 1 δ/ε, which have been found to phosphorylate and 
cause Yap degradation, suggest the conservation of such an inhibitory complex (42). Therefore, 
discoveries of upstream signals that connect tissue organization to Yap regulation in mammalian 
cells are of tremendous interests. 
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Figure 1-3.  Yes-associated protein (Yap) is the endpoint of the Hippo kinase cascade that 
modulates tissue homeostasis.   
 
Yap and its homolog Taz (or WWTR1) are subjected to regulation by hyper-phosphorylation by 
LATS1/2 and Casein kinase (CK1δ/ε), leading to nuclear exclusion and proteasomal degradation. These 
events prevent Yap/Taz from binding to and enhance transcriptional function of factors such as Tea-
domain (TEAD) family, SMAD family, p53-related protein (p73), Runt-related transcription factor 
(RUNX), and Epidermal growth factor receptor 4 (ErbB4). 
 
Unlike in Drosophila system, only a few upstream regulators, which relay signals from the cell 
membrane to the Hippo kinases, are established. These includes the neurofibromatosis type 2 (NF2 or 
Merlin) tumor suppressor, WW and C2 domain containing 1 (WWC1 or KIBRA), and Ras association 
(RalGDS/AF-6) domain family member 1 (RASSF1A).
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1.5. THE LIVER KINASE B1 (LKB1/ STK11) CONTROLS BOTH METABOLISM AND 
TISSUE STRUCTURE 
 
 Another major regulator of tissue structure and organ size is the serine–threonine protein 
kinase LKB1 (liver kinase B1). Despite its name, LKB1 is ubiquitously expressed and it controls 
a wide range of cellular functions that include metabolism, polarity, and proliferation (44). LKB1 
heterozygous patients suffer from Peutz-Jeghers syndrome that is characterized by 
gastrointestinal hamartomas and increased cancer predisposition. LKB1 inactivation is also 
frequently observed in sporadic non-small cell lung and cervical carcinomas (44, 45).  
 LKB1 functions in complex with the pseudokinase STRAD and the scaffolding protein 
MO25. This LKB1 complex directly phosphorylates and activates AMP-activated protein kinase 
(AMPK) and 12 related kinases (46) (Figure 1-4). In response to the high levels of AMP 
accumulated during glucose starvation, AMPK suppresses mTOR complex 1 (mTORC1), a 
central regulator of cell metabolism. The suppression of mTORC1 by AMPK is mediated by the 
activation of a GTPase-activating protein (GAP) called tuberous sclerosis protein 2 (TSC2). 
TSC2 in turn inactivates a small GTPase Rheb, a potent activator of mTORC1. mTORC1 is 
reported to phosphorylate a number substrates including S6 ribosomal protein kinase (S6K) and 
eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1), both involved in promotion 
of protein synthesis and cell size. mTORC1 also regulates many other cellular processes 
including protein synthesis, autophagy, lipid synthesis, mitochondrial metabolism/biogenesis, and 
cell cycle (47). LKB1 promotes efficient AMP-induced activation of AMPK and inhibition of 
mTORC1, thus inducing growth arrest in response to metabolic stress (48). Furthermore, AMPK 
also regulates transcription factors; activating FOXO3 and inhibiting CRTC2, HDAC5, and p300 
(49). These transcription factors mediate transcriptional control of metabolism. Thus, 
AMPK/mTORC1 is regarded as the canonical pathway that mediates LKB1 tumor suppressor 
effects.   
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 The role of LKB1 in suppressing gastrointestinal hamartomas, non-small cell lung, and 
cervical carcinomas implies LKB1 tumor suppressor function in the epidermis. Indeed, 
knockdown of LKB1 results in a loss of epithelial organization and increases Myc-dependent cell 
proliferation (23). Remarkably, LKB1 is the only protein whose activation is sufficient to polarize 
intestinal epithelial cells even in the absence of cell–cell contacts (50). The promotion of polarity 
by LKB1 is mediated by many signaling pathways (49). In general, LKB1 and its complex 
phosphorylate, translocate, and activate key kinases. These kinases include the microtubule 
affinity-regulating kinases (MARKs, also known as partitioning defective 1, par-1, kinases) 
family, the kinase suppressor of Ras 1 (KSR1), mammalian STE20-like protein kinase 4 (Mst4), 
AMPK, and brain-specific kinases (BRSK 1/2 or snRNP assembly-defective SAD1) (49). These 
kinases participate in a number of conserved polarity complexes to phosphorylate many 
substrates (illustrated in Figure 1-4). These substrates in turn facilitate the dynamics of 
microtubules and actin cytoskeleton for the formation of cell polarity. For instance, LKB1 
phosphorylates and activates MARKs (par-1). MARKs in turn phosphorylate microtubule-
associated proteins 2 and 4 (MAP2 and 4) and Tau (microtubule-associated protein tau, MAPT) 
for the regulation of microtubules (51-53). Alternatively, MARKs antagonize Dishevelled 
through phosphorylation and differentially regulate β-catenin and c-Jun N-terminal kinase (JNK) 
pathways downstream of Wnt activation (54) or E-cadherin engagement (55). Aside from 
metabolic control, LKB1-induced AMPK activation also promotes ZO-1 redistribution and 
enhancement of tight junctions (49). Additionally, upon E-cadheren engagement, the 
translocation of LKB1 complex with STRAD and MO25 recruits kinases like Mst4, which in turn 
activate Ezrin for the formation of brush border polarity (56, 57). In short, cellular polarity is a 
balancing act of cytoskeleton adjustment and protein distribution with LKB1 playing an essential 
part in regulation of key kinase activities.  
 While it is clear that LKB1 promotes cell polarization, it is unclear how tissue structure 
arising from this polarization leads to growth arrest. This thesis is the first study to examine the 
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possibility of cross-talk between LKB1 and the Hippo pathway in the suppression of cancer 
growth. 
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Figure 1-4.  LKB1 is a master kinase that controls a wide range of substrates and cellular 
functions. 
 
LKB1, in complex with the pseudokinase STRAD and the scaffolding protein MO25, directly 
phosphorylates and activates AMP-activated-protein-kinase (AMPK α, β, and γ) and 12 related kinases.  
 
These families of kinases are: Microtubule affinity-regulating kinases (MARK 1, 2/PAR1, 3, and 4), 
Brain-specific kinase (BRSK 1, 2/snRNP assembly-defective SAD1), Salt-inducible kinase (1, 2/QIK, 
and 3/QSK), SNF-related kinase (SNRK), SNF1-like kinase1/AMPK-related kinase 5 
(NUAK1/ARK5), and SNF1/AMP kinase-related kinase (NUAK2/SNARK). 
 
The above kinases, in turn, phosphorylate and regulate a variety of substrates includes: Mammalian-
target-of-rapamycin Complex 1 (mTORC1), acetyl-CoA carboxylase (ACC), HMG-CoA reductase 
(HMGCR), H6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) that regulate 
metabolism and cell growth. Forkhead box O3 (FOXO3), CREB-regulated transcription coactivator 2 
(CRTC2), histone deacetylase 5 (HDAC5), and p300 histone acetyltransferase regulate transcription of 
metabolic genes. Dishevelled (Dvl), partitioning defective 3 (PAR3), kinase suppressor of Ras1 
(KSR1), microtubule-associated protein (MAP), and microtubule-associated protein tau (Tau) that plays 
different roles in establishment of cell polarity. 
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1.6. THE SCAFFOLDING PROTEIN NF2 SUPPRESSES PROLIFERATION, IN PART, 
THROUGH THE INHIBITION OF YAP 
 
 A key suppressor of cell growth in response to cell-cell contact is Neurofibromatosis type 
2 (NF2), also known as Moesin-ezrin-radixin-like protein (Merlin). The NF2 gene was first 
discovered due to its loss/mutation causing a dominant inherited tumor predisposition syndrome. 
Despite confusion due to the disease name, NF2 is not related to neurofibromatosis type 1 (cause 
by the mutation of the NF1 gene). NF2 is still classified as neurofibromatosis due to historical 
diagnosis even though NF2 patients infrequently have neurofibromas. In contrast, 
neurofibromatosis type 2 syndrome is characterized by the development of multiple 
schwannomas and meningiomas. These tumors cause a variety of symptoms such as hearing loss, 
imbalance, nausea or true vertigo, and a predisposition to other types of tumors (58). About 70% 
of NF2 patients have skin tumors ranging from intracutaneous lesions to more deep-seated 
subcutaneous tumors. These patient phenotypes strongly suggest the role of NF2 as a tumor 
suppressor. Similarly, NF2 heterozygous mice develop a variety of malignant tumors (59, 60). 
The NF2 deficient tumors derived from these mice have a greatly increase metastatic potential 
(59). Other studies also confirmed that NF2 plays a role in suppressing cancer cell proliferation, 
migration, and survival in melanoma (61), glioma (62), mesothelioma, and meningioma cells (63, 
64).  
 NF2 (or Merlin) suppresses cell growth though its membrane-cytoskeleton scaffolding 
functions. The loss of NF2 leads to the activation of integrins, growth factor receptors, and 
receptor tyrosine kinases (RTKs) (65-68). The upregulation of integrins, such as integrin α6-β1 
and -β4, enhances cell adhesion to the ECM and proliferation, while decreasing apoptosis (66, 
69). NF2-deficient schwannoma cells release insulin-like growth factor-binding protein-1 
(IGFBP-1) that functions through β1 integrin to activate focal-adhesion-kinase (FAK) and Src to 
promote growth (69). Additionally, NF2 forms a complex with E/N-cadherins and β-catenin; 
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thus, schwannoma cells have disrupted adherens junctions and upregulation of the Wnt/β-catenin 
pathway (70). Alternatively, NF2 promotes the endocytosis and recycling of at least four types of 
RTKs, including ErbB, vascular endothelial growth factor receptor (VEGFR), insulin-like growth 
factor 1 receptor (IGF1R), and platelet derived growth factor receptor (PDGFR) (71). The 
increased surface availability of these receptors leads to a strong activation of Ras/Raf/MEK/ERK 
and PI3K/AKT pathways in NF2 deficient cancer cells (72). Yet another mechanism of NF2 
action is activation and membrane recruitment of the small GTPases Rac1, RhoA, Cdc42, and 
Ras (68, 73-75). Activation of these small GTPases might be a result of the above membrane 
proteins upregulation or a direct suppressing effect by NF2. For instance, NF2 expression might 
disrupt a complex composed of the ezrin/radixin/moesin (ERM) proteins, Grb2, SOS, Ras, and 
filamentous actin; therefore, NF2 inhibits growth factor signals mediated by Grb2-SOS (68). 
Alternatively, NF2 suppresses the Rac and Cdc42 downstream effector p21 activated kinases 
(PAKs) and subsequently JNK (74, 76). Thus, the loss of NF2 causes cell growth through the 
activation of a small GTPase at the membrane.  
 Interestingly, NF2 is structurally similar to the ERM proteins (72). Like ERM proteins, 
NF2 binds to and regulates the actin cytoskeleton. Unlike ERM proteins, the disruption of 
intramolecular interaction (“open” conformation) causes NF2 translocation away from the 
membrane (77, 78). A negative feedback exists whereby PAK phosphorylates NF2 on Serine 518 
and dissociates NF2 from the cell membrane (77-79). Alternatively, cyclic AMP-dependent 
protein kinase A (PKA) also phosphorylates NF2 at this same residue (80). This phosphorylation 
promotes heterodimerization of NF2 and Ezrin (an ERM protein) which blocks NF2’s 
suppression of cell growth (77). Additionally, homozygous knockout of NF2 is embryonic lethal 
to both mice and flies (81, 82), suggesting a non-redundant role of NF2 in development.  
 In addition to the above functions, NF2 (Merlin) also regulates the Hippo/Yap pathway. 
Similar to the Expanded-Merlin-Kibra complex in Drosophila, mammalian NF2 functions with 
Kibra and Expanded to regulate contact growth inhibition through the inhibition of Yki/Yap (61, 
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63, 64, 83). The knockdown of NF2 increases Yap expression and nuclear localization, and Yap 
activation is required for the increased proliferation and loss of contact inhibition in NF2-
deficient mesothelioma and meningioma cells (63, 64). In melanoma and glioma cells, NF2 
suppression of Yap is mediated by the activation of the Hippo kinase Mst and Lats (61-63). 
Surprisingly, in breast epithelial MCF10A cells, NF2 activates Lats independent of both Mst1 and 
2 (43). A different study in epithelial cells, which confirmed NF2 negative regulation of Yap, 
found Yap phosphorylation independent of both Mst and Lats (32). These results suggest a 
possible redundancy of kinases in the epithelial cell while the scaffolding function of NF2 might 
be essential for bringing together growth inhibitory complexes.  
 
1.7. HPV-E6 AND ITS DOWNSTREAM TARGETS CONTRIBUTE TO CERVICAL CANCER 
DEVELOPMENT 
 
1.7.1. HPV-E6 – a viral protein that inhibits differentiation, apoptosis, and cellular 
polarity 
 As mentioned in section 1-1, persistent infection of high-risk HPV strains is the most 
common initiating event in the development of cervical cancer. Among viral proteins expressed 
early in the life cycle of HPV, two viral proteins E6 and E7 are responsible for cellular 
transformation. E7 binds to the retinoblastoma protein (pRb) and disrupts its complex formation 
with E2F transcription factors. Thus E7 can remove pRb’s inhibition of the cell cycle and 
promote proliferation (2, 84, 85). E6 interacts with various cellular proteins and concomitantly 
with an E3 ubiquitin ligase called E6AP (86, 87). These interactions promote E6AP dependent-
ubiquitination and proteasomal degradation of proteins that bind to the E6-E6AP complex. The 
major effects of E6, including the prevention of apoptosis and differentiation, are dependent on its 
degradation of the p53 tumor suppressor. p53 directly regulates a number of pro-apoptotic genes 
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as well as the Notch transcription factor, which plays an important role in promoting 
differentiation (88, 89).  
 However, p53 inhibition does not account for all E6 effects as some E6 mutants defective 
in p53 binding/degradation are still capable of preventing keratinocyte differentiation and 
apoptosis. Blocking these two processes leads to genomic instability (84, 90, 91). Furthermore, 
E6 from high risk HPV strains also enhances cancer malignancy by increasing cell spreading and 
adhesion. Therefore, other cellular targets of this multifunctional E6 protein are also of research 
interest for therapeutic purpose. Interestingly, high risk HPV-E6 is reported to promote the 
degradation of a number of PDZ domain-containing proteins such as hScrib, hDlg, MAGI, 
MUPP1, PATJ, and PTPN3 (92). These proteins are reported as parts of various polarity 
complexes and have crucial roles in cell junctions and tissue structure (93, 94). Consistent with 
this observation, the PDZ domain-binding motif was required for high-risk 31E6 to promote 
keratinocytes growth on organotypic raft cultures (95). These results suggest a possible role of E6 
in disruption of contact inhibition.  
 
 1.7.2. Rap1 – a small GTPase with roles in junction formation and cell adhesion 
 A screen for cellular proteins targeted for degradation by the high risk HPV 16E6 
identified E6-targeted protein 1 (E6TP1, Sipa1L1) (96, 97). Like p53, E6TP1 was also shown to 
be ubiquitinated by E6AP and targeted for proteasomal degradation (98). E6TP1 was later found 
to be a GTPase-activating protein (GAP), which deactivates a family of small molecular switch 
proteins, Ras-proximate protein (Rap) (96). There are several closely related members of the Rap 
family include Rap1A, Rap1B, Rap2A, Rap2B and Rap2C. Rap proteins are members of the Ras 
family. Like Ras, Rap shuttles between active GTP-bound and inactive GDP-bound states, upon 
activation by guanine nucleotide exchange factors (GEFs) and deactivation by GAPs (99). Rap1 
and Rap2 exhibit 60% sequence identity and share a number of GEFs and GAPs. Redundant and 
distinct functions of Rap1 and Rap2 are still under investigation. Rap1 and Rap2 were first 
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considered as Ras antagonists because they compete for the Ras-binding domain of Raf-1 (also 
known as c-Raf) but do not activate it. This competition for Raf binding by Rap interferes with 
Ras transformation. Later, Rap1 was found to promote proliferation in cells that contain B-Raf 
through activation of the ERK mitogen-activated protein kinases pathway (100). Additionally, 
Rap2 may activate JNK through MAP4K4 to promote growth (101). Despite Rap1’s possible 
roles in cell growth and transformation, its most notable roles are in cell junction formation, cell 
migration, and cancer invasiveness (102-109). In immune cells, Rap1 activates various integrins 
to regulate cell migration in response to chemokine signals. Increased Rap1 activity is associated 
with various types of leukemia and their malignancies (99, 110, 111). Rap1 also plays an essential 
role in the hematopoietic system where stem cells’ attachment to their niche is important for their 
maintenance and functions (99, 112). On the other hand, Rap1 activation of integrins leads to 
increase cell-cell adhesion of endothelial and epithelial cells. Rap1 is also required for the 
maturation of adherens junctions through its regulation of vascular endothelial (VE)-cadherin 
(113) and epithelial (E)-cadherin (105). Since Rap1 regulates both cell-cell and cell-extracellular 
matrix (ECM) adhesion, it may have positive or negative influences on cancer development, 
depending on the specific cell type and its micro-environment (99). Intriguingly, Mina Bissell’s 
lab reported that Rap1 is a crucial regulator of breast epithelial acinar structure in three-
dimensional assays (114). Active Rap1 promotes cell growth and suppression of Rap1 activity 
restores tissue polarity and induces lumen formation (114). Thus at least in breast epithelial 
tissue, Rap1 up-regulation is a promoter of cancer malignancy.  
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1.8. HELA CELL AND NORMAL KERATINOCYTE (NTERT) ARE USED IN THIS STUDY 
 
 In order to understand the connection between tissue structure and growth control, this 
study utilized two cell lines: HeLa and normal keratinocytes (NTERT). These cell lines represent 
both ends of the spectrum in cervical cancer development. HeLa is a cervical cancer cell line that 
has not been manipulated to grow in cell culture. This cell line was isolated from a patient named 
Henrietta Lacks in 1951. HeLa has the high-risk HPV-18E6 and 18E7 genes integrated into its 
genome. HeLa also has 84 chromosomes (four copies of chromosome 12, three of 6, 8, and 17) 
and c-myc amplification. Although HeLa has been passaged for many decades in the tissue 
culture, its genome has remained astonishingly stable. This cell culture model interested us 
because HeLa cells have completely lost contact inhibition of growth and do not have LKB1 
expression (115). Extraordinarily, LKB1 restoration to HeLa cells alone can recue cell polarity 
and contact inhibition, as further discussed in the results section of this thesis. This rescue also 
did not require the overexpression of LKB1 scaffold proteins such as STRAD and MO25. Thus, 
the ability to control the polarity of a cancer cell with a single protein expression is a great 
research tool.  
 On the other end of the spectrum, NTERT keratinocytes originated from normal human 
keratinocytes immortalized with hTERT. These cells have spontaneously lost p16INK4A expression 
bypassing the p16-imposed control of the pRb pathway. The molecular event for p16 loss has not 
been determined; although, reports suggest the mutation of the trans-acting regulator of p16. 
NTERT cells have normal p53 expression, EGF-dependent proliferation, and are sensitive to 
growth inhibition by phorbol esters (116). They also retain LKB1 expression and contact 
inhibition of cell division. Furthermore, they retain normal expression of differentiation markers 
such as keratin and involucrin, and form normal differentiating epidermal layers in organotypic 
culture (116). Additionally, NTERT cells have a normal genome without HPV integration. Thus, 
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NTERT cells are a normal and differentiable cell model which we can use to understand LKB1 
and E6 downstream effects on tissue structure and Yap. 
 
1.9. RATIONALE AND CENTRAL HYPOTHESIS 
 
The overarching goal of this dissertation is to identify the molecular mechanisms that 
underline the ability of tissue structure to inhibit Yap and ultimately to suppress oncogenesis of 
cervical cancer. This central goal was formulated based on the published literature of Yap 
dominant roles in cell proliferation and Yap suppression in response to tissue structure formation 
and contact inhibition of cell division. Two events that lead to cervical cancer were examined in 
the context of Yap regulation: the loss of LKB1 tumor suppressor and the expression of the HPV-
E6 viral oncogene. The rationale for the studies of these proteins is that both LKB1 and HPV-E6 
affect cellular polarity and tissue structure. Furthermore, clinical studies showed that the loss of 
LKB1 associates with malignancy and greatly worsens the prognosis of HPV-positive cervical 
cancer (7, 115, 117). Thus, my central hypothesis is that Yap mediates cell growth regulation 
downstream of LKB1 loss and HPV-E6 expression in the promotion of cervical cancer. To test 
this hypothesis, three Aims were pursued: 1) Determine LKB1 regulation of Yap and cellular 
proliferation. 2) Examine the requirement of NF2 (Merlin), actin reorganization, and cellular 
polarity for LKB1 suppression of Yap. 3) Investigate the role of HPV-E6 and its downstream 
target E6TP1–Rap pathway in the inhibition of cell differentiation and the promotion of Yap 
activity. 
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2.1. GENERAL CELL CULTURE METHODS 
  
  NTERT keratinocytes cells (116) were grown in GIBCO keratinocyte media at 60 μM 
CaCl2 supplemented with bovine pituitary extract (BPE), epidermal growth factor (EGF), and 
penicillin-streptomycin antibiotic mixture. For passaging, cells were washed once with Phosphate 
Buffered Saline (PBS), treated for 5 mins with Trypsin EDTA, and resuspended in Dulbecco’s 
Modified Eagle Medium (DMEM)/ 10% fetal bovine serum (FBS) (Atlanta Biologicals). This 
step was added due to the lack of trypsin EDTA inactivating agents in normal keratinocyte media. 
The mixture was then spun down at 800 rpm for 5 mins. The high calcium media was removed 
and replaced with growth media. NTERT cells were induced to differentiate with 2.8 mM CaCl2 
added to growth media. Cells were frozen slowly in 10% DMSO + complete keratinocyte media. 
HeLa, 293gp, and 293T cells were grown in DMEM/antibiotics /10% FBS. The passaging 
method was the same as for NTERT cells except the spin down step was not necessary. Cells 
were frozen slowly in 10% DMSO + 20% FBS + DMEM. 
 
2.2. GENERATION OF STABLE CELL LINES USING LENTI-VIRUS 
 
 Expression vector carrying gene of interest or pLKO vector carrying shRNA in 
combination with packaging plasmids (pRSV-REV, pMDLg/RRE, and VSV-G lenti) were 
transfected into 293T cells via calcium phosphate precipitation. Half the medium volume 
(example 5 ml for 10 cm plate) was changed next day. The following day, lenti-viruses were 
harvested and passed through 0.45 μm filters. Target cells were plated into filtered lenti-viral 
media containing a final concentration of 5 μg/ml polybrene. 48 hrs later, cells were selected in 
1μg/ml puromycin until mock-transduced cells (no plasmid) were dead (usually 2 days exposure). 
Certain stable cell lines with growth disadvantage such as HeLa cells expressing LKB1 cells will 
lose expression after roughly 3 passages.   
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2.3. GENERATION OF STABLE CELL LINES USING RETRO-VIRALLY EXPRESSED 
HPV-16E6 
 
pLXSN retroviral vector encoding HPV-16E6 was obtained from Dr. Roman’s lab. 
Retrovirus was made by Lipofectamine-Plus transfection of this construct into Phoenix-ampho 
SD3443 cells (already stably express retroviral coating proteins). Alternatively, pLXSN-E6 in 
combination with VSV-G retro plasmid was transfected into 293gp cells via calcium phosphate 
precipitation or XtremeGeneHP. Half the medium was replaced next day. The following day, 
retro-viruses were harvested and passed through 0.45 μm filters. Viral supernatants with 1μg/ml 
polybrene were used to infect NTERT cells. After 3-6 hrs, cells were washed with PBS and 
returned to normal keratinocyte medium. Plates were split after 2 days and selected with 200 
μg/ml G418 to establish stably expressing cell lines. 
  
2.4. PLASMIDS, ANTIBODIES, AND CELL LYSIS BUFFERS 
 
LKB1 was subcloned into pCDH (Systems Biosciences) following PCR amplification 
using EcoRI/NotI. Two plasmids available in the pCDH system: pCDH-Hygro (for untagged 
LKB1) and pCDH-Puro (LKB1 separate from GFP by a cleavable peptide). Both plasmids are for 
the generation of stable cell lines using lenti-virus delivering system. Alternatively, LKB1 was 
subclone into pQCXI-puro (Clonetech) via NotI/EcoRI sites for flag tagged protein. Rap1 WT 
and mutants were subcloned from pFlag-CMV using BglII/EcoRI sites and compatible overhang 
BamHI/EcoRI sites to pEGFP. Subsequently, the GFP-Rap1 fusion fragments were subcloned 
into pCSCG lenti viral vector using AgeI/SalI sites with partial SalI digestion. Note that pCSCG 
does not have mammalian selection. The GAP proteins such as E6TP1, KIAA1389, and SIPA 
were subcloned into donor vector 309-linker of the Creator System using a two-step-procedure. 
This vector 309-linker was modified from v309 to have polylinker with additional cloning sites 
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(see Appendix for more details). The two-step-cloning procedure involved subcloning the N-
terminal portion (from 5’-AscI site up to an internal restriction site) following PCR amplification. 
Then the C-terminal portion was inserted to the same plasmid using internal and 3’end restriction 
sites. The N-termini of E6TP1, KIAA1389, and SIPA were flanked by AscI/HindIII, AscI/XhoI, 
and BamHI/StuI, respectively. Similarly, the C-termini were moved with HindIII/XbaI, 
XhoI/SpeI, and StuI/XbaI, respectively. The latter sites (XbaI and SpeI) were destroyed during 
cloning, thus flanking these GAPs remained AscI/PacI sites. RapGAPs were subcloned on the 
second reading frame into v309-L2 with modified polylinker using BglII/XbaI sites. Once again 
these sites were destroyed during cloning. cDNAs in donor vector 309 were recombined into 
acceptor vector with various tags such as myc, flag, GFP, CFP, and RFP using a homemade 
recombinase enzyme. Other plasmids included 5xGal4-luc (118). Gal4-Tead4, 2xFlagYap WT, 
S127A, S5A were purchased from AddGene (#24640, 19045, 27370, and 27371). pCDH-
FlagYap WT and mutants were subcloned from above plasmids into pCDH-linker (a derivative of 
pCDH-Hygro containing a polylinker of multiple cloning sites) using NotI/XbaI. Vector YFP-
occluden, cerulean-H2B, and botulinum C3 expression constructs were gifts from Clark Wells 
lab. Non-targeting controls were a scrambled luciferase sequence in pLKO.1 (Addgene #1864) 
for shRNA and ON-TARGET Plus (Dharmacon D001810-10-05) for siRNA. 
Antibodies: Phospho-YapS127, LKB1, S6, phospho-S6, Phospho-acetyl coA carboxylase 
(ACC) and total ACC (Cell signaling), total Yap (Abnova), b-actin and U1snRNP (Santa Cruz), 
GAPDH (Meridian Life Science), NF2 and Taz from Wells lab (Cell signaling). 
RIPA lysis buffers for whole cell lysate (WCL): buffer consisted of 50 mM Tris7.4, 150 
mM NaCl, 2 mM EDTA, 1% Triton X-100, 1% SDS. Additives were phosphatase inhibitors 5 
mM NaF and 10 mM beta-glycerol phosphate, and proteasome inhibitors PMSF and aprotinin 
concentrations 
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2.5. TRANSIENT TRANSFECTION METHODS 
 
2.5.1. Calcium Phosphate precipitation cellular transfection method 
This method was used to transfect 293T cells for protein expression or lenti virus 
generation. In short, the appropriate amount of plasmid DNA, CaCl2, and water were mixed. An 
equal volume of 2X HEPES buffered saline (HBS – 6.5g HEPES, 8g NaCl, 0.2g Na2HPO4-
7H2O in 500 mL water, pH 7.05) was added to the DNA mixture drop-wise with continuous 
vortex for form a fine precipitation. After 20 mins at room temp, the final mixture was added to 
plates of 293T cells. For virus generation, 2 to 3 million cells per 10 cm plate were required.  
 
2.5.2. XtremeGene (Roche) transfection method 
This method caused minimal cytotoxicity and could be used for a number of different cell 
lines including HeLa cells. Roche’s protocol was followed. In short, serum- and antibiotic-free 
DMEM was used. Plasmid DNA and transfecting reagent were incubated in this media for 15 to 
30 mins. The mixture was then added to the cells (in regular growth medium), followed by next 
day media change. 
 
2.5.3. Lipofectamine-2000 (Invitrogen) transfection method 
This method was more cytotoxic but was required for the efficient transfection of siRNA. 
Briefly, cells were washed once with PBS and placed in serum- and antibiotic-free DMEM. 
Plasmid DNA and transfecting reagent were also incubated in this media for 15 to 30 mins. The 
mixture was then added to the cells for 3 to 4 hrs. Then cells were washed and placed back in 
normal media.    
Note: a number of transfecting reagents and methods were tried on NTERT 
keratinocytes; however, transfection efficiency was low 10 to 20% at best. Thus, NTERT had to 
be infected for gene expression or knockdown studies. 
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2.6. THE EXPRESSION AND PURIFICATION OF GST-FUSION PROTEINS IN BACTERIA  
 
 pGEX RalGDS RBD or other proteins with GST-fusion were retransformed into E.coli 
strain Rosetta for protein production. Small culture was grown at 37C overnight with Ampicillin 
antibiotic before transfer to 500 mL culture. Large culture was grown to ~OD 0.6 to 0.8 at 600 
nm (usually 3 hrs). Bacteria cells were induced with IPTG at 18C overnight. Upon harvesting, 
cells were lysed in GST Bacterial Lysis Buffer (20 mM Tris 8.0, 500 mM NaCl, 1 mM EDTA, 
1% TritonX-100). Three different methods can be used to homogenize the bacterial mixture: 
French Press, freeze-thaw and passage through a 20G syringe, or sonication. A combination of 
syringe passage and sonication were acceptable. Homogenous mixture were spun down at 10,000 
rpm for 20 minutes and the supernatant were collected contain GST-fusion proteins. These can be 
load onto PBS washed GSH beads for precipitation assay of snap freeze in aliquots.     
 
2.7. RAP1 ACTIVITY ASSAY 
 
NTERT keratinocyte were differentiated for the indicated days. Cells were lysed in cold 
condition to prevent GTP hydrolysis such as cold PBS wash, cold tumble, and cold RAL Lysis 
Buffer (50 mM Tris pH 7.4, 200 mM NaCl, 2.5 mM MgCl2, 10% Glycerol, and 1% IGEPAL) 
supplement with proteasome inhibitors. Rap1-GTP was measured by precipitation of Rap1-GTP 
from described keratinocyte lysates using a GST fusion protein containing the ras binding domain 
(RBD) of RalGDS immobilized on agarose beads as described (119). Bound proteins were eluted 
off the beads using sample buffer, size-separated by SDS-PAGE, transferred to Immobilon 
membrane, and blotted with Ras 142-24E05 antibody (that recognizes Rap1). 2 to 5% input lysate 
were also immunoblotted with Ras142 antibody to compare total Rap1 levels between samples. 
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2.8. THE RELATIVE QUANTIFICATION OF RNA LEVELS 
 
RNA was isolated using TRIzol (Invitrogen) according to the manufacturer’s protocol. 
Briefly, cells were homogenized in TRIzol reagent prior to the addition of chloroform. Following 
phase separation, RNA was precipitated from the aqueous fraction using 50% isopropanol, 
washed with 70% ethanol, and dissolved in RNase-free water. First strand cDNA synthesis using 
M-MuLV reverse transcriptase was performed according to New England Biolabs protocol. This 
protocol involves 2 μg RNA, oligo dT primer, dNTP, RNAse inhibitor (Promega), buffer, and 
reverse transcriptase. Since oligo dT was used as primer, only mRNA containing polyA should be 
made into cDNA. Next, qRT-PCR detection of transcripts was performed using LightCycler-
RNA Master Mix (Roche) and the Roche Universal Probes Library according to the 
manufacturer’s protocol. Primer sequences and probe numbers are listed in the appendix. CTGF 
mRNA levels were normalized to GAPDH or RPLP0 (ribosomal protein, large, P0) expression. It 
is worth noting that the mRNA level of actin changes dramatically and GAPDH level also 
exhibited a small change upon LKB1 knockdown in NTERT cells; thus, RPLP0 is the only 
reliable standard in this case. 
 
2.9. THREE DIMENSION MATRIGEL ASSAY (17)  
 
Each stable cell line was trypsinized and 2 x 105 cells were plated between two layers of 
growth factor reduced Matrigel matrix (BD). Briefly, plates were pre-coated with a thin layer of 
Matrigel for 20 mins at 37C. After addition of cells, 10% Matrigel solution was used as top 
overlay. Full serum media was changed every 2 days. After 8-10 days, cell clumps were 
visualized using a Stereo Microscope (Nikon SMZ1500).  
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2.10. TEAD REPORTER ASSAY 
 
0.1 μg Gal4-Tead4 and 0.8 μg 5xGal4-luc were transfected using either 
Lipofectamine2000 (Invitrogen) or XtremeGene HP (Roche). Two days later, firefly luciferase 
signals were measured in cell lysates using Promega kit (E153A and E1483) and a BioSystem 
Luminometer. 
 
2.11. CELL ACCUMULATION ASSAY 
 
Stable cell lines were seeded sparsely at 5 x 104 cells/plate into six or nine identical 35 
mm plates. At the indicated times, three of these plates were trypsinized and resuspended in 500 
μl media. Immediately, 50 μl of the cell suspension were mixed with 50 μl trypan blue and cells 
counted on a hemocytometer. 
 
2.12. NUCLEAR FRACTIONATION METHOD 
 
After PBS wash, attached cells were incubated in Fractionation Buffer (10 mM HEPES 
7.9, 1.5 mM MgCl2, 10 mM KCl, 0.2% IGPAL) for 15 mins at 4C. If phospho-proteins were 
measured, the aforementioned phosphatase inhibitors were added. The IGPAL detergent amount 
was increased up to 1% for differentiated NTERT cells for cleaner fractionation. Cells were spun 
for 10 mins at 3,000 rpm. The cytoplasmic fraction was removed and remaining cell nuclei pellets 
were washed twice and resuspended in RIPA buffer for 10 mins. Nucleic fraction was collected 
by spinning for 10 mins at 14,000 rpm.  
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2.13. FLUORESCENCE MICROSCOPY 
 
For immunofluorescence staining, cells were plated on treated cover glass (Deckglaser) 
placed inside culture plates. Two days later, cover glasses were carefully removed, washed, and 
fixed with 100% methanol at -20C for 8 minutes. Endogenous Yap was stained with Yap 
antibody and Texas red secondary antibody (Invitrogen T862) according to Cell Signaling’s 
immunofluorescence protocol. Fluorescence images were taken with AxioVisionCam using a 
Zeiss Observer confocal microscope. 
For live cell imaging of fluorescent proteins, cells were seeded sparsely on MatTek glass 
bottom plates (P35G-0-14-C). Two days after transfection of fluorescent protein-encoding 
plasmids, cells were viewed with the above Zeiss microscope. 
 
2.14. CELL SIZE ANALYSIS 
 
Cells were plated on 60 mm plates two days ahead of analysis. Cells were trypsinized and 
resuspended in DMEM/10% FBS media. The mixture was then spun down, media was removed 
and replaced with 200 to 500 μl of PBS + 0.2% BSA. Cell sizes were analyzed with a 
FACSCalibur machine. First measurement by red/green channels separated different populations 
with high or low LKB1-GFP expression. The mean forward scatter (FSC) of each population 
above was calculated and normalized to vector control to obtain relative cell size. Three samples 
of each population were analyzed for average relative cell sizes ± std dev.   
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2.15. DRUGS, EGTA TREATMENT, AND NUTRIENT STRESS 
 
The following drug concentrations and manufacturers catalog numbers were used: 100 
μg/ml cycloheximide (Sigma #66-81-9), 10 μM MG132 (CalBiochem #474790), 250 μM Torin1 
(N.S.Gray DFCI). 
EGTA treatment of HeLa cells with LKB1 restoration was incubation with DMEM 10% 
FBS, 25 mM HEPES, and 4 mM EGTA. Since DMEM has 2.8 mM Ca2+, this treatment was 
closed to 1 mM EGTA treatment. 
Nutrient stress: glucose starvation used glucose deficient DMEM (GIBCO 11966) with 
10% FBS, Glutamine starvation use DMEM no glutamine. 
 
2.16. WESTERN BLOT, DENSITOMETRY, AND STATISTICS 
 
WB (immunoblot): WCL or immunoprecipitates were resolved on 10-12% SDS-PAGE 
and transfer to PVDF-FL membranes for immunoblotting. Immunoreactive bands were visualized 
with ECL, ECL Prime (GE Healthcare, Piscataway, NJ), or Supersignal Femto (Pierce) reagents. 
Films were developed using ALL-PRO 100 Plus processor. Alternatively, P-Yap and total Yap 
proteins (antibodies from different species) were viewed simultaneously using the Odyssey 
infrared imaging system (Biosciences). 
Densitometric images from three independent experiments were quantified using ImageJ 
software (NIH). Normalized data is presented as mean + standard deviation (error bars).  
P-values from Student T-test. ANOVA one-way were done with Origin 8.5.1 software. 
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CHAPTER 3. LKB1 REGULATES AMPK/MTOR-INDEPENDENT CELL GROWTH 
AND PROLIFERATION VIA THE INHIBITION OF YAP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Some text and figures in this Chapter are copied from a publication by Nature Publishing 
Group:  
 
Nguyen HB, Babcock JT, Wells CD, and Quilliam LA. LKB1 tumor suppressor regulates AMP 
kinase/mTOR-independent cell growth and proliferation via the phosphorylation of Yap. 
Oncogene (2012) doi:10.1038/onc.2012.431  
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3.1. INTRODUCTION 
   
  Growth and development are regulated by a balance between proliferation and apoptosis 
that is linked to tissue structure through poorly understood mechanisms. Deregulation of this 
balance results in the hyperproliferation of cancer cells as well as gross changes in cell 
morphology and tissue organization (120). For instance, the malignancy of cervical cancer, which 
arises from the epithelial layer of the cervix, is categorized by the degree of tissue 
disorganization. Thus, tissue structure is believed to be a tumor suppressing mechanism that 
controls cell proliferation. Recently, two crucial pathways have emerged that govern this 
mechanism: the Hippo pathway and signals triggered by LKB1. The Hippo pathway inhibits Yap 
transcription co-activator from promoting transcription of proliferative genes. Coordinately, 
Hippo suppression of Yap mediates contact inhibition of cell division, regulates tissue 
maintenance, and is a major regulator of organ size (29, 49). On the other hand, the tumor 
suppressor LKB1 is a master regulator of metabolism and apical-basal polarity. LKB1 reduces 
cell size and cell cycle through the central regulators of metabolism AMPK and mTORC1 (49). 
Additionally, LKB1 provides resistance to hyperplasia through establishment of epithelial 
structure (23); however, it is unclear how LKB1-promoted polarity suppresses cell growth. 
Despite the strong logical link between these two pathways, no evidence of their association has 
previously been reported.   
 Using HeLa cells that lack LKB1 expression, or alternatively suppressing its expression 
in non-transformed human keratinocytes, we now show that the regulation of cell size and 
proliferation by LKB1 are at least in part mediated by Yap inhibition. In HeLa, LKB1 restoration 
increased Yap phosphorylation, leading to nuclear exclusion and decreased stability. LKB1-
induced growth arrest and cell size shrinkage could be partially reversed by expression of 
phosphorylation-defective Yap mutants. Similarly, LKB1 knock-down by shRNAs in 
keratinocytes increased cell sizes and endogenous transcription of CTGF, a Yap downstream 
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effect. Interestingly, these phenomena occurred independently of mTOR, AMPK or Lats1/2 
activation, suggesting a non-canonical pathway links LKB1 activity to Yap phosphorylation. This 
work identifies a novel link between two major tumor suppressor pathways and a potential 
mechanism for cell polarity to restrict cancer cell growth. 
 
3.2. RESULTS 
 
 3.2.1. LKB1 functions in promoting apical-basal polarity 
 Epithelial tissue structure is established through the formation of cell-cell junctions and 
apical-basal polarity whereby certain organelles and proteins are asymmetrically distributed. 
Interestingly, LKB1 is the only reported protein whose activation is sufficient to polarize 
intestinal epithelial cells in the absence of cell–cell contacts (50). Reciprocally, knockdown of 
LKB1 results in a loss of epithelial organization and increases Myc-dependent cell proliferation 
(23). Since cervical cancer cells such as HeLa have lost apical-basal polarity and lack LKB1 
expression, HeLa was chosen as our cancer model cell line. Using lentiviral transduction, LKB1 
was stably expressed in HeLa cells (HeLa LKB1), in contrast no LKB1 was detected in HeLa 
cells stably expressing GFP alone (HeLa Vec) (Figure 3-1, left panel). Alternatively, lenti-virus 
carrying shRNAs targeting LKB1 were used to suppress its endogenous expression in 293T 
kidney cells or NTERT non-transformed human keratinocytes (Figure 3-1, left panel). Consistent 
with previous report of LKB1 function, phase contrast images of cells with LKB1 restoration and 
knockdown showed that LKB1 promotes an epithelial-like morphology even in cancer cell lines 
(Figure 3-1, right panel). This polarized morphology promoted by LKB1 was even more 
pronounced when HeLa LKB1 cells were grown in three-dimensional matrix (in later Figure 3-6 
A). 
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Figure 3-1.  LKB1 expression promotes an epithelial-like cell morphology.   
HeLa cells, that lack LKB1 expression, were transduced with lentivirus expressing LKB1 or GFP 
vector control. Alternatively, endogenous expression of LKB1 in 293T cells was suppressed using 
target specific shRNA. LKB1 expression was confirmed with immublot (left panel) and phase-contrast 
images of these cells were taken (right panel). 
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 3.2.2. LKB1 tumor suppressor is a novel inhibitor of Yap oncoprotein 
 The Hippo pathway functions as part of a crowd control mechanism to limit organ size by 
reducing cell proliferation (29). In cultured cells, Hippo signaling is activated by high cell 
density, leading to phosphorylation and inhibition of the transcriptional co-activator Yap (29). 
Meanwhile, the tumor suppressor LKB1 promotes polarity as seen in above figure. To investigate 
the potential for crosstalk between LKB1 and the Hippo pathway, the effect of LKB1 expression 
on the inhibitory phosphorylation site YapS127 (37), was measured. Correlated with epithelial-like 
morphology even at low cell density, LKB1 expression raised the phospho-YapS127/total Yap 
ratio to a level comparable to that seen in the NTERT non-cancerous immortalized human 
keratinocytes (Figure 3-2 A). Alternatively, the knockdown of LKB1 using two different shRNAs 
in NTERT cells promotes an increase in Yap protein level (Figure 3-2 B). These data suggested 
an inhibitory relationship between LKB1 and Yap. 
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Figure 3-2.  LKB1 increases Yap phosphorylation and knockdown of LKB1 increases total Yap 
protein. 
A. The relative levels of Yap, phospho-YapSer127, LKB1 and -actin were detected by immunoblot 
analysis of HeLa cell lysates prepared following infection with lentivirus expressing LKB1 (HeLa 
LKB1) or GFP control (HeLa Vec) vectors and compared to uninfected NTERT immortalized human 
keratinocytes. The mean ratio of phospho-YapSer127/YapTotal from three experiments is indicated 
below a representative immunoblot. Error was computed as standard deviation of the mean.  
B. NTERT cells were infected with two independent lentiviruses encoding LKB1 shRNAs (#1 and #2) 
or a non-specific control sequence. After stable selection on puromycin, the relative levels of 
endogenous LKB1 and GAPDH from these lysates were measured by immunoblot.  
Blots are representatives of at least three independent experiments.  
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3.2.3. LKB1 expression reduced proliferative gene transcription downstream of Yap in 
HeLa and NTERT  
 Yap binds and stimulates the transcriptional activity of Tea-domain (TEAD) transcription 
factors to promote cell growth (121). Thus, Yap activity was inferred by TEAD-induced gene 
expression from a luciferase reporter system. HeLa cells were co-transfected with TEAD reporter 
and LKB1, a kinase dead LKB1, or vector control. The expression of LKB1 reduces the 
luciferase signals by approximately 5 fold. This inhibition required LKB1 kinase activity since 
the kinase-dead mutant failed to suppress luciferase activity (Figure 3-3 A). To test the effect of 
LKB1 on exogenously expressed Yap, we transfected cells with various ratios of LKB1- and 
Yap-encoding plasmids. Remarkably, this reporter system is sensitive to as little as 20 ng of 
exogenous Yap. While no changes were observed upon transfection of control vector, increasing 
the amount of transfected LKB1-encoding plasmid resulted in dose-dependent inhibition of Yap 
activity (Figure 3-3 B). Another measure of Yap activity is the transcription of connective tissue 
growth factor (CTGF) (121). Consistent with TEAD-luciferase data, LKB1 restoration drastically 
reduced CTGF mRNA level (Figure 3-3 C). Conversely, we employed shRNAs to examine the 
effect of endogenous LKB1 knockdown on Yap activity in NTERT keratinocytes. Suppression of 
LKB1 expression by two separate shRNAs greatly enhanced CTGF transcription as determined 
by qRT-PCR in NTERT (Figure 3-3 D) and TEAD activity in 293T cells (Figure 3-3 E). These 
data clearly indicated that LKB1 expression inhibits Yap transcriptional function.   
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Figure 3-3.  LKB1 inhibits Yap dependent transcription in HeLa, 293T, and NTERT cells. 
A. HeLa cells were co-transfected with a luciferase reporter system containing a TEAD response 
element along with WT LKB1, kinase-dead LKB1, or empty vector. Yap-dependent transcription was 
inferred from luciferase signals after 48 hr and LKB1 expression confirmed by immunoblot. 
B. TEAD-driven transcription was measured as in part A using HeLa cells transfected with the 
indicated amount of LKB1 and Yap expressing plasmids (fixed Yap level). 
C. Endogenous HeLa cell CTGF transcript was measured by RT-PCR following infection with control 
or LKB1-encoding plasmids. Stable LKB1 expression confirmed by immunoblot. 
D. CTGF mRNA was measured in NTERT cells as in part B following stable expression of LKB1 
shRNAs #1 or #2 or a non-specific control sequence. Knockdown confirmed by immunoblot. 
E. TEAD assay as in part A and knockdown as in part D using 293T cells. 
Luciferase data are representatives of at least three independent experiments performed in triplicate. 
qRT-PCR is representative of two experiments performed in quadruplicate. Error was computed as 
standard deviation of the mean. Significance was computed by student T-test where p-values are 
indicated by * < 0.05; ** < 0.01; *** < 0.001. 
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3.2.4. LKB1 regulates Yap via cytosolic retention and proteasomal degradation of Yap 
protein 
Yap dependent transcription is inhibited via the hyperphosphorylation of Yap on multiple 
sites. Currently, there are 5 known Lats1/2 phosphorylation sites on Yap (42). Among these, 
phospho-serine 127 allows for 14-3-3 binding and Yap cytoplasmic retention (38). In order to 
evaluate whether this spatial regulation occurs in LKB1 cells, we employed both nuclear 
fractionation and fluorescence microscopy. Firstly, hypotonic lysis was used to separate nucleic 
and cytoplasmic fractions. Endogenous Yap from both fractions was then detected by western 
blotting. We independently fixed cells and visualized the subcellular localization of endogenous 
Yap protein by immunofluorescence microscopy. Consistent with the increased phospho-
YapS127 level in LKB1 expressing cells, both localization methods showed a significant 
decrease in nuclear Yap protein in HeLa LKB1 cells comparing to HeLa Vec cells of the same 
plating density (Figures 3-4 A and C). Consistently, knockdown of LKB1 in NTERT cells caused 
a significant increase in nuclear Yap (Figures 3-4 B). We concluded that LKB1 restoration 
increases S127 phosphorylation, promoting Yap nuclear exclusion. 
Since proteasomal degradation is another important Yap regulating mechanism (29), we 
examined whether LKB1 add-back decreases Yap protein stability. To monitor the stability of 
Yap, HeLa LKB1 and HeLa Vec cells were treated with cycloheximide (CHX) to inhibit new 
protein synthesis. Plated at low density, HeLa Vec exhibited insignificant decrease in Yap protein 
level over 6 hours of CHX treatment. Meanwhile, Yap level rapidly decreased in LKB1 cells 
(Figure 3-4 D). To confirm that the decrease in Yap level was due to proteasomal degradation, we 
used the proteasome inhibitor, MG132. As previously observed, we saw a significant decrease in 
Yap level in LKB1 cells treated with CHX alone compared to DMSO control. However, addition 
of MG132 along with CHX returned Yap protein to control level (Figure 3-4 E). These results are 
consistent with previously shown LKB1 knockdown in NTERT cells caused an increase in total 
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cellular Yap protein (Figure 3-2 B). Altogether, these results indicated that LKB1 decreases Yap 
stability by promoting its proteasomal degradation. 
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Figure 3-4.  LKB1 inhibits Yap nuclear localization and promotes the degradation of Yap protein 
by the proteasome. 
A. The relative levels of Yap, phospho-YapSer127, LKB1, U1snRNP (nuclear marker), and β-actin 
(cytosolic marker) were measured by immunoblot from nucleus- and cytosol-enriched fractions 
prepared from HeLa cells stably expressing LKB1 (HeLa LKB1) or GFP control vector (HeLa Vec). 
The average levels of Yap protein from three experiments are indicated in right panel next to a 
representative blot in left panel. 
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B. NTERT cells were treated as in part A to measure Yap levels in nuclear and cytosol enriched 
fractions. 
C. HeLa LKB1 and HeLa Vec cells were fixed and immunostained for Yap. Nuclei were counterstained 
with DAPI. 
D. HeLa LKB1 and HeLa Vec cells grown at low density were treated with 100 μg/ml cycloheximide 
(CHX) for the indicated times. The levels of Yap, phospho-YapSer127, LKB1 and β-actin were 
measured by immunoblot analysis from cell lysates (upper panel). The average Yap levels from three 
independent experiments were also computed (lower panel). 
E. HeLa LKB1 and HeLa Vec cells were treated with CHX and 10 μM MG132 for 2 hr. Protein levels 
were then measured by immunoblot analysis (left panel). The average levels of Yap from three 
independent experiments are also shown (right panel). 
Errors and significances are represented as in Figure 3-3. 
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3.2.5. Mutation of phosphorylation sites on Yap desensitize Yap from LKB1 effects and 
 rescue LKB1 suppression of proliferation 
Figure 3-1 demonstrated that LKB1 expression induces phosphorylation of YapSer127. This 
correlated with decreased Yap nuclear localization and transcriptional co-activation. We 
hypothesized that if Yap phosphorylation was the key event triggered by LKB1 expression to 
regulate gene expression and cell growth, then blocking such phosphorylation event(s) would 
rescue LKB1 tumor suppressor phenotypes. Two phosphorylation-defective Yap mutants were 
used in addition to a wild type (YapWT) construct to test this hypothesis: YapS127A has Ser 127 
mutated to Ala while the Yap5SA mutant lacks all five reported Lats phosphorylation sites (S61, 
S109, S127, S164, and S381) (42). The Yap5SA mutant additionally has Ser 128, 131, and 163 
mutated to Ala; however, these mutations do not affect cell growth and are not Lats 
phosphorylation sites (37). The TEAD-luciferase reporter assay was used as above to monitor 
Yap activity following transient transfection. While YapWT activity was inhibited by LKB1, the 
S5A mutant was insensitive to LKB1 action (Figure 3-5 A). A statistically insignificant but 
reproducible inhibition of YapS127A activity by LKB1 suggested that additional Yap 
phosphorylation sites might also play a role in suppressing its activity (Figure 3-5 A). These 
results suggested that Yap phosphorylation is required for LKB1 to suppress gene expression.  
A major effect of LKB1 tumor suppressor expression was a strong reduction in 
proliferation of HeLa cells. This effect was measured by directly counting trypan-blue excluded 
cells on the indicated days. Correlated with the increase in Yap phosphorylation, LKB1 
expression causes over 2-fold reduction of proliferation in HeLa LKB1 cells that was similar to 
the growth rate of NTERT cells (Figure 3-5 B). Since the transcriptional activity of Yap phospho-
mutants was not inhibited by LKB1, we next addressed whether these mutants could rescue the 
suppression of proliferation seen following LKB1 expression. Lenti-viruses encoding LKB1 and 
various Yap transcripts were used to co-infect HeLa cells. After puromycin selection, cell 
accumulation was monitored as part B. Despite LKB1 suppressing endogenous Yap activity, the 
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expression of the Yap5SA mutant significantly promoted cell proliferation (Figure 3-5 D). 
Consistent with the transcriptional activity data (Figure 3-5 A), the YapS127A mutant had a weaker 
effect than Yap5SA on rescuing cell proliferation. Meanwhile, YapWT expression did not 
significantly change cell growth (Figure 3-5 D). In the absence of LKB1, the overexpression of 
Yap WT and mutants also did not significantly change cell accumulation (Figure 3-5 C). We 
concluded that the hyper-phosphorylation of Yap contributes to LKB1-mediated suppression of 
cell proliferation. 
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Figure 3-5.  The ability of LKB1 to suppress Yap dependent transcription and cell growth is 
partially reversed by phosphorylation-deficient Yap mutants.  
A. HeLa cells were transfected with Yap- wild type (WT), S127A, or 5SA in combination with vector 
control or LKB1. TEAD dependent transcription was measured as described in Fig 6a.  
B. After seeding 5x104 cells/plate, trypan blue-excluded cells were counted in triplicate on the indicated 
days by hemocytometer. The mean number of HeLa Vec (◊) or HeLa LKB1 (■), and NTERT 
immortalized human keratinocytes (▲) were plotted. 
C. HeLa cells were infected with lenti-viruses carrying vector control (◊), YapWT (■), YapS127A (▲), and 
Yap5SA (x) mutants. Following hygromycin selection, cell accumulation was measured as in part B. 
D. HeLa cells were co-infected with LKB1 virus and others viruses as in part C. Following puromycin 
selection for LKB2 expression, cell accumulation was measured as in part B.   
Error and significance are represented as described in Figure 3-3. 
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3.2.6. Yap5SA mutant rescued cellular proliferation but not cell-cell compaction promoted 
by LKB1 
 Recently, the technique of three dimensional (3D) cultures has been developed for better 
understanding of tissue polarity. In addition to cell-cell interaction available in 2D monolayer, 3D 
culture also provides cell-ECM interaction due to Matrigel matrix enrichment of the laminin 
substrate. Many cancer promoting pathways were confirmed to cause disturbance to the polarized 
structure of epithelial acini, and the suppression of these signals restore acini structure in 3D 
culture (17). Therefore, we examined the effect of LKB1 and Yap5SA expression on HeLa cell 
growth in a 3-dimensional Matrigel matrix. The above stable cell lines were plated at low density, 
submerged in two layers of matrix for 8 to 10 days. Consistent with our previous data from 2-
dimensional culture, HeLa cells have completely loss cell polarity; they grow and spread into flat 
invasive colonies. The restoration of LKB1 significantly reduced cell growth in Matrigel as well 
as promoting polarized cell clumps (Figure 3-6 A, bottom left panel). Interestingly, Yap5SA 
expression greatly increased cell proliferation both in the presence and absence of LKB1 but did 
not disrupt LKB1-induced cell-cell compaction. Somewhat vary from 2D result, the expression of 
either YapWT or YapS127A did not altered cell growth pattern nor cell cohesion (Figure 3-6 B). This 
result further supported the role of Yap hyper-phosphorylation in mediating LKB1 suppression of 
proliferation but not LKB1 promotion of polarity.  
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Figure 3-6.  The expression of Yap5SA mutant rescues LKB1 growth suppression effect but not 
LKB1 polarity effect in 3D Matrigel culture. 
HeLa cells stably expressing the indicated cDNAs were imaged after 10 days culture in Matrigel. 
Representative images are shown. Insets are 2-fold increase magnification of colonies. 
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3.2.7. Phosphorylation-defective Yap mutants partially reversed cell size reduction by 
LKB1 
 Cell size is a complex phenotype that is often influences by proliferative state and could 
be the outcome of various distinct pathways (122, 123). Various studies have reported the 
regulation of cell and organ size by both LKB1 and the Hippo pathway. For example, conditional 
knockout of murine LKB1 resulted in increased islet beta cell volume (124). Meanwhile, Yap 
conditional overexpression in other tissues was reported to cause liver enlargement and 
thickening of epidermal layers (34, 125). Therefore, we examine whether LKB1 regulates HeLa 
cell size by inhibiting Yap. Utilizing the HeLa LKB1 and HeLa Vec cells described above, we 
first confirmed the ability of LKB1 to reduce cell size. The lentiviral pCDH plasmid encodes for 
both GFP and LKB1, thus LKB1 levels could be correlated with GFP fluorescence. Two distinct 
populations were observed in GFP/LKB1 add-back cells; those that expressed high levels of 
recombinant proteins and those that had much lower levels (Figure 3-7 A). While the relative 
volume of low GFP/LKB1-expressing cells was similar to HeLa Vec cells, consistent with 
previous reports (45, 124), the cells highly expressing LKB1 had significantly smaller average 
size (Figure 3-7 B). Meanwhile, knockdown of LKB1 in NTERT cells increased cell volume 
(Figure 3-7 C) confirming LKB1 function in cell size reduction.  
 To address whether the inhibition of Yap contributed to this effect, lenti-viruses carrying 
YapWT or the phosphorylation-defective S127A or 5SA mutants were co-transduced with LKB1-
encoding virus into HeLa cells. While YapWT had no effect, YapS127A and Yap5SA mutants 
significantly rescued LKB1-induced cell size reduction (Figure 3-7 D). The Yap5SA mutant was 
most effective, again suggesting contribution of phospho-sites other than S127 in mediating 
LKB1’s effects. However, even Yap5SA expression did not completely return HeLa cells to 
control size (Figure 3-7 D). Thus, inhibition of Yap may be just one factor contributing to 
suppression of cell volume by LKB1. 
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Figure 3-7.  LKB1-induced cell shrinkage is partially reversed by the expression of YapS127A or 
Yap5SA.  
A. HeLa cells infected with a lentivirus carrying LKB1 and GFP (separated by a T2A self-cleaving 
peptide) or GFP alone were analyzed by flow cytometry forward scatter (FSC). Two sub-populations 
were observed in GFP/LKB1 add-back cells: one with high and one with low GFP signal.  
B. The mean FSC of each population described in part A was calculated as an arbitrary unit of cell size, 
which was then normalized to vector control to obtain relative cell size. Three samples of each 
population were analyzed and the average relative sizes presented.  
C. NTERT cells with LKB1 knockdown or non-target control were treated as in part A and B. 
D. Stable cell lines generated from co-infection with LKB1 and Yap transcripts as described in Figure 
3b were sorted by GFP signals/LKB1 expression. Cell sizes were then analyzed.  The mean FSCs were 
normalized to vector control, averaged from three samples, and presented as mean ± S.D.  
All results are representative of at least two independent experiments performed in triplicate. * p < 
0.05; ** p < 0.01; N.S. not significant 
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3.2.8. Neither AMPK nor mTOR activity mediated LKB1’s regulation of Yap 
 Numerous studies have reported that LKB1 regulates cell size through activation of 
AMPK and subsequent inhibition of mTORC1-induced protein synthesis via phosphorylation of 
TSC2 and/or raptor (49). Since Yap phosphorylation-defective mutants were found above to 
reverse LKB1-induced cell size reduction, we next addressed whether LKB1 regulates Yap via 
mTOR activation. The ATP analogue Torin1 (126) was used to effectively block both mTORC1 
and C2 activities. To activate mTORC1, we overexpressed its upstream regulator, Rheb (119). 
mTORC1 activates S6 kinase (S6K), promoting ribosomal S6 protein phosphorylation to control 
protein synthesis and cell size (127). Thus we used phospho-S6K as a read-out for mTORC1 
activity (Figure 3-8 A). As expected, Torin1 reduced and Rheb increased phospho-S6K level. 
However, changes in mTORC1 activity did not influence the ability of LKB1 to inhibit Yap 
activity (Figure 3-8 B). This suggested that LKB1 inhibits Yap independently of mTOR. Since 
Yap mutants only partially rescued LKB1 effects on cell size and proliferation (Figures 3-5 D, 3-
6, and 3-7 D), we speculate that Yap and mTOR mediate independent aspects of signaling 
downstream of LKB1. Surprisingly, the inhibition of mTORC1 by the drugs Torin1 (Figure 3-8 
B) and rapamycin, or by glutamine starvation (Figure 3-8 D) caused a small but significant 
increase in Yap activity (ANOVA one-way p<0.01). Since mTORC1 is a major metabolic sensor, 
this enhancement implies a possible negative feedback regulation between these two pathways 
downstream of LKB1. 
 LKB1 directly phosphorylates AMPK, enabling efficient activation upon AMP elevation, 
thus allowing cells to quickly response to metabolic stress (49). In order to examine possible 
mTOR-independent effects of AMPK on Yap, we induced metabolic stress via glucose starvation. 
AMPK phosphorylates acetyl-CoA carboxylase (ACC) to reduce glucose metabolism (128). 
Therefore we measured phospho-ACC as a positive control for AMPK activation. In this 
experiment, YapS127 phosphorylation was measured instead of Yap transcriptional activity due to 
the short duration of the experiment precluding significant changes in luciferase expression. 
59 
 
Although AMPK was strongly activated by 1-3 hr of glucose starvation (large increase in ACC 
phosphorylation), Yap phosphorylation remained unchanged (Figure 3-8 C). Thus we concluded 
that LKB1 inhibits Yap independently of AMPK activation.  
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Figure 3-8.  LKB1 regulates Yap independently of mTOR or AMPK activation.  
A. LKB1 directly phosphrylates and activates AMPK, which in turn inhibits mTORC1 directly and 
through inactivation of Rheb activator. 
B. HeLa cells were co-transfected with LKB1, Rheb and/or control vector as indicated. After 24 hr, 
cells were treated with the mTOR kinase inhibitor Torin1 (250 nM) for 16 hr. TEAD-luciferase activity 
was then measured as in Figure 3-3. HA-Rheb, LKB1, phospho-S6K, total S6K and β-actin were 
measured as controls for protein expression and mTOR activity. 
C. HeLa Vec and HeLa LKB1 cells were glucose starved for up to 3 hr as indicated. Lysates were then 
immunoblotted to measure phospho-YapSer127, Yap, phospho- and total acetyl CoA carboxylase (ACC), 
LKB1 and β-actin. AMPK activation was confirmed by increased ACC phosphorylation. The average 
levels of phospho-YapSer127 from three experiments are indicated in lower panel. 
D. HeLa cells were transfected with TEAD reporters and treated with Rapamycin for 24hrs or 
glutamine starve overnight 
Figures B and C are representative of three experiments, Figure D is representative of two experiments. 
Errors and significance are as described in Figure 3-3. ANOVA one way was performed to compare 
groups of four data points. N.S. not significant 
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 3.2.9. LKB1 suppression of Yap function might not require Lats1/2 kinases  
 Neither one of the five phosphorylation sites included in the Yap5SA matches LKB1 
consensus substrate motif thus it is likely that LKB1 suppression of Yap is indirect. The 
consensus motif is DFGØsnXØXXgX--XLXTØCGSPXYAaPE with Ø represents a large 
hydrophobic residue; X, any amino acid; s, n, g and a preferences for Ser, Asn, Gly and Ala, 
respectively (46). The ability of Yap5SA to revert the effects of LKB1 expression additionally 
suggested Lats1/2 kinases may couple LKB1 to Yap suppression due to Guan’s report of Lats1/2 
kinases phosphorylating these sites. To examine this, we transiently knocked down Lats1 and/or 2 
using siRNA and measured Lats protein levels and TEAD-driven luciferase activity. Surprisingly, 
suppression of Lats1/2 expression did not impact the ability of LKB1 to suppress Yap activity 
(Figure 3-9 A). Although Lats1/2 knockdown partially rescued TEAD activity, LKB1 caused the 
same fold of activity suppression with and without Lats knockdown. Additionally, we 
immunoblotted HeLa LKB1 and control cell lysates for the Mst phosphorylate and activating site 
on Lats1 site T1079. LKB1 expression causes a decrease in both P-Lats and total Lats protein 
(Figure 3-9 B with total Lats quantified in right panel). This evidence argued against Lats 
mediating LKB1 effect. Together, these result suggested that either LKB1 regulated Yap activity 
via a non-Hippo pathway or there were redundancy in kinases that phosphorylate Yap in the 
mammalian system. 
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Figure 3-9.  Yap suppression by LKB1 does not require Lats kinases.  
A. HeLa cells were transiently transfected with indicated siRNAs, LKB1 or vector control, and TEAD 
luciferase plasmids.  TEAD-luciferase activity as well as Lats 1, Lats2, LKB1 and GAPDH were then 
measured. 
B. WCL from HeLa cells stably expressing LKB1 were immunoblotted for Lats1 kinase, LKB1, and β-
actin (left panel). The average levels of Lats1 protein from three blots were quantified in right panel. 
All results are representatives of at least three independent experiments. Error and significance are 
represented as described in Figure 3-3.  
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3.3. DISCUSSION 
 
3.3.1. A novel polarity-growth connection in which LKB1 suppresses Yap leading to 
decreased cell proliferation and cell size 
 The architecture of a cell contributes to its survival, proliferation and function. A key 
component of this architecture is the establishment of apical-basal polarity whereby certain 
organelles and proteins are asymmetrically distributed. Polarity is established though a variety of 
signaling complexes that are integrated into the control of proliferation by poorly defined 
mechanisms. Recently, the Hippo (Mst-Lats-Yap) signaling pathway has emerged as a major 
growth regulator with its endpoint, phosphorylation and inactivation of the Yap transcriptional 
co-activator, being regulated by cell polarity/structure (32, 40). Interestingly, the LKB1 tumor 
suppressor is currently the only protein reported to cause cellular polarization in a cell 
autonomous fashion (50). The data reported here reveal a novel polarity-growth connection in 
which LKB1 activity regulates the subcellular distribution and proteasomal degradation of Yap 
leading to decreased cell proliferation and cell size (illustrated in Figure 3-10). 
 The master kinase LKB1 is required for epithelial structure-related resistance to 
hyperplasia (23). LKB1 promotes epithelial structure at least in part by regulating the Par-3/Par-
6/atypical protein kinase C tight junction complex (129); however, how this structure prevent cell 
division is largely unknown. Consistent with a previous report in intestinal epithelial cells (50), 
expression of LKB1 autonomously promotes the polarization of HeLa cells in 2- and 3-D 
cultures. LKB1 also suppresses cell proliferation and its re-expression in HeLa cells reduced their 
growth rate to that of non-transformed human keratinocytes. Since the Yap transcriptional co-
activator is a key regulator of cell growth in response to cell polarity, we examined the effect of 
LKB1 by its re-expression in HeLa cells and suppression of endogenous LKB1 gene expression 
in NTERT or 293T cells. LKB1 expression inhibited the ability of both endogenous and 
exogenously expressed Yap to induce the activation of a well-characterized luciferase-coupled 
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TEAD response element as well as endogenous CTGF transcription. These data demonstrated for 
the first time that Yap activity is closely associated with LKB1 status of tumor cells. Furthermore, 
LKB1 is known to suppress growth through the activation of AMPK and subsequently the 
inhibition of mTOR activity and protein synthesis. Indeed, no other signaling pathway 
downstream of LKB1 has been found to be activated in human tumors following LKB1 loss (49, 
130). However, neither the activation of AMPK by glucose starvation nor pharmacological 
inhibition of mTOR activity impaired LKB1-mediated Yap phosphorylation. Therefore, the Yap 
transcriptional co-activator mediates LKB1’s tumor suppressor functions independent of the 
canonical AMPK/mTOR pathway. Since Yap directly promotes the expression of proliferative 
genes, these findings indicate an alternative mechanism for LKB1-mediated suppression of 
cancer cell growth.   
 In many developmental systems and malignancies, the localization, integrity, and 
function of Yap are tightly regulated by its phosphorylation status. Consistently, we found that 
each of these parameters was closely linked to LKB1 expression in HeLa and NTERT cells. 
Specifically, LKB1 promoted phosphorylation of Ser127 that correlated with nucleus to 
cytoplasmic localization and enhanced Yap degradation. The decrease in nuclear Yap levels in 
LKB1 expressing cells also correlated with reduced proliferation of 2 and 3 dimensional cell 
cultures as well as cell size. Importantly, the expression of phosphorylation-resistant Yap mutants 
but not the overexpression of WT Yap reversed all impacts of LKB1 expression on gene 
expression, cell growth and cell size. These data support the notion that LKB1 impacts cell 
growth via Yap phosphorylation and inhibition.  
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Figure 3-10.  LKB1 suppression of Yap is a novel polarity-growth connection.   
Aside from the regulation of metabolic sensors AMPK/mTORC1, LKB1-induced cell polarization 
impacts cell growth through the suppression of Yap transcription co-activator. This suppression is 
caused by the cytosolic retention and proteasomal degradation of Yap proteins as a result of Yap hyper-
phosphorylation. 
Red connecting lines in above diagram represent novel findings while black lines represent previously 
reported results. Arrows are promoting events while T-ended lines stand for inhibition. Dashed line is 
indirect effect. 
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3.3.2. The mechanism of Yap regulation is an integration of multiple pathways and 
requires the hyper-phosphorylation of Yap  
 Mass spectrometry analysis of Yap protein isolated from MCF10A cells done by Guan’s 
lab reveals 10 unique phosphorylation sites (42). Five of these sites match the consensus 
sequence of Lats1/2 includes S61, S109, S127, S164, and S381. Interestingly, unlike the other 
phosphorylation sites, the mutation of S381 to alanine did not increase YAP electrophoretic 
mobility when isolated protein was run on gel that specifically retards phosphorylated proteins 
(Figure 1B of this report). Nonetheless, using a S381/S384 phospho-specific antibody, Lats1/2 
was found to phosphorylate Yap on this S381 site and prime Yap for further phosphorylation by 
casein kinase δ/ε on nearby S384 and S387 sites. The phosphorylation of these sites in 
combination with nearby sequence (called phosphodegron sequence) is a recognition signal for 
the binding of the E3 ubiquitin ligase β-TRCP for Yap degradation. Lats1/2 were also required 
for the phosphorylation of Ser127 for Yap cytosolic retention. Altogether, the 
hyperphosphorylation inhibits Yap activity and the ability of Yap phospho-mutants to partially 
reversed the effects of LKB1 expression were consistent such a role. The Yap5SA mutant has all 
five phosphorylation sites mutated, including the S381 priming site for degradation of Yap, while 
the Yap127A mutant only has mutation at the cytosolic retention signal. Both the Yap5SA and 
Yap127A mutants were resistant to LKB1 suppression using the TEAD reporter assay; however, we 
observed a small but reliable suppression of the Yap127A mutant by LKB1. Yap S127 and S381 
double mutant (Yap2SA) likely has the same effect as Yap5SA (42). Consistent with previous 
reports indicating greater activity of the Yap5SA mutant (42), it was also more effective than 
Yap127A at rescuing LKB1 growth suppression in 2D cultures. Strikingly, the expression of the 
degradation-resistant Yap5SA mutant reverted LKB1’s growth inhibitory activity without 
disrupting LKB1-induced cell cohesion in 3D culture (most evident in Figure 3-6 A). Meanwhile, 
neither YapWT nor Yap127A mutant has any effect with or without LKB1 in this condition (Figure 
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3-6 B). Thus, these results suggest that degradation rather than mere exclusion from the nucleus 
plays a role in LKB1-induced events.  
 None of the phosphorylation sites targeted in the Yap5SA mutant match an LKB1 
consensus motif, suggesting indirect kinase or phosphatase regulation. Since the AMPK-related 
kinase, NUAK1/ARK5 is a substrate of LKB1 that phosphorylates Lats (131), we first considered 
it as a mediator of Lats/Yap regulation. However, phosphorylation by ARK5 has been 
documented to destabilize Lats1 (131, 132) which would likely reduce phospho-Yap levels. 
Consistent with this report, we also observed a decrease in Lats1 protein level upon LKB1 
expression, which could be related to ARK5 activity (Figure 3-9 B). Since LKB1 inhibits Yap, 
this decrease in Lats protein level is inconsistent with Lats or ARK5 mediating the inhibitory 
LKB1 effect. While we did observe a faster turn-over of Yap protein upon LKB1 expression, 
similar to that reported seen upon Lats activation (42), we did not see a role of Lats in Yap 
regulation by LKB1. The knockdown of Lats1/2 expression in HeLa cells did not prevent LKB1 
from inhibiting Yap (Figure 3-9 A). Although Lats1/2 expression was not completely suppressed, 
this data strongly suggested that LKB1-induced inhibition of Yap does not require the Lats 
kinases. Conditional knock out of Mst1/2 in mouse or siRNA knock down of Mst1/2 and Lats1/2 
similarly did not change Yap phosphorylation pattern or TEAD activity in keratinocytes (32). 
Additional reports similarly described increased Yap phosphorylation and nuclear exclusion in 
the absence of the Mst/Lats kinases (41, 133). These results together suggest that at least in 
mammalian epithelial cells, a non-Mst/Lats kinase might also be involved in the suppression of 
Yap activity. 
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CHAPTER 4. THE SCAFFOLD NF2 IS REQUIRED FOR LKB1 TO PROMOTE 
ACTIN REORGANIZATION AND YAP INHIBITION  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
One figure in this Chapter is copied from a publication by Nature Publishing Group: 
 
Nguyen HB, Babcock JT, Wells CD, and Quilliam LA. LKB1 tumor suppressor regulates AMP 
kinase/mTOR-independent cell growth and proliferation via the phosphorylation of Yap. 
Oncogene (2012) doi:10.1038/onc.2012.431 
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4.1. INTRODUCTION 
 
 Previously in chapter 3, we identified Yap as a novel inhibitory target that mediates the 
growth suppressing effect of LKB1. This chapter 4 is devoted to the molecular mechanism by 
which LKB1 activity causes Yap nuclear exclusion and degradation. Since the metabolism 
regulators AMPK/mTORC1 are not involved in Yap suppression, LKB1 promotion of cellular 
polarity is the focus of the current chapter.  
 LKB1 promotes cellular polarity through the activation of MARK family, Mst4, AMPK, 
and BRSK kinases (49). These downstream kinases are part of various polarity complexes and in 
turn facilitate the assembly of microtubules and actin cytoskeleton. Additionally, many 
scaffolding proteins that conduct signals from plasma membrane to the cytoskeleton also 
contribute to cell polarity. For instance, LKB1 activates MARK2, which directly phosphorylates 
Tau. This event promotes the destabilization of microtubules (51-53). Alternatively, the kinase 
Mst4 is recruited to the cell membrane through its direct binding with the scaffolding protein 
MO25α (a part of LKB1 complex). This recruitment leads to the phosphorylation and activation 
of Ezrin (an ERM protein) and consequently the formation of brush borders (56, 57). Thus the 
organization of cytoskeleton and the membrane localization of scaffolding proteins are important 
consequences of LKB1 activation.  
 On the other hand, the scaffolding protein NF2 mediates contact-dependent inhibition. 
NF2 inhibits cell growth both through membrane-cytoskeleton signaling and the Hippo/Yap 
pathway. The loss of NF2 results in up-regulation of membrane associated proteins such as 
integrins, growth factor receptors, and receptor tyrosine kinases (RTKs) (65-68). NF2 also 
inhibits Rac1-mediated activation of PAK. These regulations of RTKs and Rac1-PAK by NF2 
reduce MAPK signaling as well as cell proliferation (61, 72, 134). Additionally, NF2 is a 
negative regulator of Yap (35, 64, 83). NF2 expression activates the Hippo kinases, Mst and Lats 
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(61-63). In epithelial cells, NF2 could also suppress Yap without the activation of Mst1/2 (43) 
and Lats (32). Nonetheless, the inhibition of Yap contributes to NF2 tumor suppressing effect.  
 NF2 shares structural homology with ERM proteins. Similar to ERM, NF2 binds to actin 
and influence cytoskeletal assembly. Unlike ERM proteins, the disruption of intramolecular 
interaction (“open” conformation) causes NF2 translocation away from the membrane (77, 78). 
This “open” conformation also promotes heterodimerization of NF2 and Ezrin (an ERM protein) 
which blocks NF2’s suppression of cell growth (77). Interestingly, Ezrin is activated as a 
consequence of LKB1 expression (135). Given NF2 functions both as Yap suppressor and actin 
regulator, this chapter will examine the potential role of NF2 in mediating LKB1-Yap regulation.  
 
4.2. RESULTS 
 
4.2.1. LKB1 promotes an epithelial-like morphology that is associated with increased 
Yap phosphorylation 
 Low activity of Yap is associated with differentiated morphology. For epithelial cells, 
this morphology involves an increase in cell polarity and the formation of cell junctions (32). As 
previously discussed, the suppression of Yap proteins is facilitated by Yap phosphorylation. This 
event leads to the redistribution of Yap from the nucleus to the cytosol and cell junctions. Yap 
junctional sequestration is mediated by the interaction with membrane proteins such as a 14-3-
3/α-catenin complex, Fat atypical cadherin, and the Amot family (31, 32, 136). Additionally, 
LKB1 restoration promoted an epithelial-like morphology with cell-cell cohesion in 2D and 3D 
culture (Figure 3-1, 3-6, and 4-1 A). In order to dissect the mechanism of Yap suppression by 
LKB1, we first confirmed whether cellular structure induced by LKB1 mediated Yap 
phosphorylation.  
 LKB1 promotion of epithelial architecture was examined by imaging live cells 
expressing fluorescently-tagged proteins. Two plasmids expressing pYFP-occluden (a component 
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of tight junctions) and pCFP-histone 2B (a nuclear marker) were co-transfected with vector or 
untagged LKB1 into HeLa cells. Fluorescence images taken from these live cells showed a 
junctional distribution of occluden in LKB1-expressing cells (Figure 4-1 B).  
 Since adherens junctions rely on Ca2+-dependent homotypic interaction of E-cadherin 
molecules (109), we disrupted cell contacts by chelating extracellular calcium and examined the 
effect on Yap phosphorylation. Upon chelation of Ca2+ with EGTA, the peripheral localization of 
occluden in LKB1-expressing cells was lost within 6 minutes (Figure 4-1 B). Ca2+-chelation also 
drastically decreased YapSer127 phosphorylation in a time dependent manner in LKB1 cells. In 
contrast, no significant change was observed in the already low P-Yap level of vector control 
cells (Figure 4-1 C). Surprisingly, the total Yap level in LKB1 cells was also slightly decreased 
(Figure 4-1 C). This suggested that cell polarity, induced by LKB1, impacts Yap phosphorylation 
and disruption of such structure lead to Yap degradation.  
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Figure 4-1.  Cellular structure promoted by LKB1 plays a role in creating and maintaining 
elevated phospho-Yap levels.  
A. Phase-contrast images suggested HeLa LKB1 cells have increase cell-cell attachment/cohesion. 
B. Cells were plated on glass-bottom MatTek dishes. YFP-tagged occluden (a component of tight 
junctions) and cerulean histone 2B (a nuclear marker) were co-transfected with vector or untagged 
LKB1 into HeLa cells. Fluorescent live cell images were taken using a confocal microscope from 
vector control, LKB1 cells, and LKB1 cells after 6 min EGTA treatment. 
C. HeLa Vec and HeLa LKB1 cells were treated with EGTA to disrupt adherens junctions for indicated 
times. Lysates from these cells were immunoblotted for phospho-YapSer127, total Yap, LKB1 and β-actin 
(upper panel).  The average levels of phospho-YapSer127 of Vec (◊) and LKB1 (■) cells from three 
experiments were also computed (lower panel). 
Blot and fluorescence images are representative. Error and significance are as described in Figure 3-3. 
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4.2.2. LKB1 promotes Occluden redistribution and the remodeling of actin structure 
When HeLa cells with LKB1 expression were plated at low density so that cell-cell 
contact did not exist, individual cell autonomously established a distinct cylindrical cell shape. 
This was consistent with Clevers’ report that LKB1 activation can polarize dissociated intestinal 
epithelial cells (50). Remarkably, even without cell cohesion, LKB1 promotes the redistribution 
of Occluden from the cytosol to cell membrane (Figure 4-2 A). This observation was done using 
the same live cell imaging technique previously described in Figure 4-1. This result suggests that 
while an extrinsic factor like cell-cell adhesions may enhance the organization of cellular 
components, such effect is an intrinsic property of an individual cell.  
Cell morphologies are established by the organization of microtubules and actin 
structures. Since actin and not microtubules have been shown to regulate Yap localization (40, 
41), we focused on whether LKB1 affects actin remodeling. Fully polarized epithelial cell with 
apical-basal protein distribution have two types of filament actin structure: cortical actin and 
stress fiber (137) (illustrated in Figure 4-2 B). Cortical actin structures are meshwork of filaments 
just beneath the plasma membrane. Meanwhile, stress fibers are contractile actin-myosin filament 
bundles that may provide driving force for the cell movement (137, 138). In order to examine 
actin filaments, we expressed LifeAct-GFP, a fluorescently-tagged peptide that specifically binds 
the polymerized F-actin and not monomeric G-actin (139). Fluorescence live cell images were 
taken from HeLa LKB1 and control cells previously transfected with LifeAct. Remarkably, 
LKB1 promoted an intricate actin structure even in the absence of cell-cell junctions (Figure 4-2 
C). The increase in actin structure was associated with the cylindrical morphology. It is possible 
that this actin organization allowed the peripheral distribution of occluden previously observed in 
Figure 4-2 A. 
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Figure 4-2.  LKB1 promotes the organization of actin structure even in the absence of cell-cell 
contact. 
A. Occluden and histone 2B in HeLa control or LKB1 cells at low density were visualized as described 
in Figure 4-1. Regardless of cell-cell junction formation, occluden is localized in a structure that 
polarized cells autonomously. 
B. cartoon illustrating the two types of actin cytoskeleton that promotes cell shapes. 
C. HeLa cells stably expressing untagged-LKB1 or control cells were transfected with plasmid 
expressing LifeAct, a GFP fusion peptide that specifically binds to F-actin but not G-actin. Actin 
structures in these live cells were visualized on MatTek plates using a fluorescence microscope as 
previously described. Pictures taken from the mid-section of the cells, white arrows denote actin 
structures. 
Fluorescence images are representative.  
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 4.2.3. An unclear role of Rho in mediating LKB1 effect 
 There are three major small GTPases responsible for cytoskeleton regulation: Rho, Rac, 
and Cdc42. LKB1 promotes actin remodeling that associated with Yap suppression. Thus we 
examined the effects of these GTPases on Yap using the TEAD reporter assay. Several 
constitutively active RhoAQ63L, RacG12V, RacQ63L, Cdc42G12V, or the fast cycling Cdc42F28L 
mutants were transiently expressed in HeLa cells in combination with TEAD reporter. RhoAQ63L 
strongly increased TEAD luciferase activity; in contrast, the expression of activated Rac and 
Cdc42 mutants did not change TEAD activity (Figure 4-3 A). Similarly, specific inhibition of 
Rho activity (140) by expressing the Clostridium botulinum exoenzyme C3 drastically reduces 
luciferase signals (Figure 4-3 B). Interestingly, the expression of dominant negative RacT17N also 
results in a suppression of Yap downstream transcription. However, this suppression by RacT17N 
is less than C3 effect and does not enhance C3 effect (Figure 4-3 B). The RacT17N mutant works 
by competing with wild-typed protein in binding to Rac activators- GEFs but cannot be activated. 
Thus, it is likely that RacT17N inhibition of Yap is an off-target effect, whereby RacT17N competes 
for GEF(s) that activate both Rho and Rac. Thus out of the three cytoskeleton regulators, only 
Rho is confirmed as a potent activator of Yap. 
 Furthermore, two recent studies reported that stress fibers control Yap nuclear retention 
and thus its transcriptional activity (40, 41). These reports are consistent with our result since 
only the Rho GTPase promotes stress fiber formation. Next we examined if the disruption of 
stress fibers couples LKB1 to the suppression of Yap activity. Interestingly, although RhoAQ63L 
mutant strongly activates Yap, LKB1 expression promoted a similar fold of Yap suppression in 
both vector control and RhoAQ63L cells (Figure 4-3 C). Additionally, a previous report showed 
that stress fiber disruption may preferentially affect the phosphorylation and stability of the Yap-
related Taz protein (41). Therefore, it remains unclear whether LKB1 disrupts stress fibers or Rho 
activation is a parallel pathway that converges on Yap/Taz regulation. 
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Figure 4-3.  Rho is a potent activator of Yap but it is unclear whether the inhibition of Rho 
mediates LKB1 effect.  
A. HeLa cells were co-transfected with plasmids expressing various Rac, Rho, Cdc42 constitutive 
active mutants, or empty vector control and TEAD reporter. Yap activity was inferred from luciferase 
signals as previously described in Figure 3-3. 
B. Similar to experiment in part A, the effects of Cdc42, Rac dominant negative mutants, and a C3 
botulinum toxin that specifically inhibit Rho were compared to vector control. Additionally, RacT17N 
mutant and C3 were combined to examine additive effect. 
C. Once again, TEAD dependent transcription was measured in HeLa with constitutively active 
RhoAQ63L mutant in combination with vector control or LKB1 expressing plasmid. 
Data representation of at least three independent experiments performed in triplicate. Error and 
significance are represented as described in Figure 3-3. 
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4.2.4. NF2 is required for LKB1 to suppress Yap 
A number of scaffolding proteins regulate contact growth inhibition through Yap 
suppression. These include 14-3-3, the Amot family, and NF2 (Merlin). 14-3-3 couples Yap 
binding to α-catenin at the adherens junctions. Meanwhile, the Amot family binds to and 
sequesters Yap at the tight junctions. The Amot family consists of several scaffolding proteins 
named Amot80, Amot130, AmotL1, and AmotL2. Additionally, NF2 (Merlin) relates signals 
from the membrane to the activation of the Hippo kinases and Yap suppression.  
In order to identify whether one or more of these scaffold proteins mediate LKB1 effect, 
two spliced variants of Amot, Amot130 and Amot80, or the NF2 protein were co-transfected in 
combination with LKB1. Yap downstream activity in these cells was then measured by TEAD 
reporting assay as previously described. Unexpectedly, both Amot and NF2 overexpression 
increased Yap activity despite their previously reported roles as Yap suppressors (Figure 4-4 B 
and C). However, this result is not unusual for inhibitory complexes, whereby the expression of 
the scaffold component may disrupt the complex stoichiometry (illustrated in Figure 4-4 A). Thus 
it is possible that Amot130 or NF2 overexpression break apart the necessary complexes for Yap 
suppression. The overexpression of both Amot spliced variants did not affect the ability of LKB1 
to suppress Yap activity (Figure 4-4 C). Although further investigation is required to confirm 
whether LKB1 function independent of other Amot family members, at least Amot80 and 130 did 
not mediate LKB1’s effect. In contrast, exogenous NF2 completely disrupts LKB1 function 
(Figure 4-4 B).  
NF2 relates external stimuli to cytoskeleton regulation. This function is achieved through 
NF2 binding to both actin cytoskeleton and the cytoplasmic ends of cell surface glycoproteins 
(78). Given our previous results implicating actin reorganization in Yap inhibition, the result of 
NF2 overexpression was confirmed with the knock down of endogenous NF2 in HeLa cells. Cell 
lines with NF2 knockdown were generated with two different shRNAs, delivered by lenti-viral 
system. Both knockdown cell lines were transfected with LKB1 or control vector and TEAD 
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reporter for the measurement of Yap downstream transcription. As expected, both NF2 
knockdown cell lines had significant increase of Yap activity, similar to NF2 expression. 
Furthermore, NF2 knockdown completely abolished LKB1’s ability to inhibit Yap (Figure 4-4 
D). Additionally, stable NF2 knockdown and LKB1 expression were achieved with dual lenti-
viral infections. Whole lysates from these cells were immunoblotted for P-Yap, total Yap, LKB1, 
NF2, and GAPDH. Consistent with activity data, Yap phosphorylation promoted by LKB1 was 
completely eliminated by the knockdown of NF2 (Figure 4-4 E). Thus far, NF2 is the only protein 
that is absolutely required for LKB1 suppression of Yap.  
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Figure 4-4.  NF2 (Merlin) is required for LKB1 to inhibit Yap. 
A. Illustration of how the overexpression of one component in an inhibitory complex, in particular a 
scaffold protein, may have the reverse effect on Yap activity. 
B. HeLa cells were transiently transfected with indicated NF2, LKB1 or vector control, and TEAD 
luciferase plasmids.  TEAD-luciferase activity was then measured as previously described. 
C. HeLa cells were transiently transfected as in part B except with indicated Amot cDNA. TEAD-
luciferase activity. Overexpression of Amot proteins was confirmed by western blot. 
D. HeLa cells were infected with lentivirus expressing shRNA targeting NF2 or non-target control. 
Subsequently, cells were transfected with TEAD reporter and LKB1 or vector control. Yap activity was 
inferred from luciferase signals. 
E. NF2 knockdown HeLa as in part D were also co-infected with lentivirus expressing LKB1 or vector 
control. Lysates from these cells were immunoblotted for P-Yap, total Yap, LKB1, NF2, and GAPDH.  
All results are representatives of at least three independent experiments, luciferase experiments were 
performed in triplicate. Error and significance are represented as described in Figure 3-3. 
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4.2.5. NF2 is required for LKB1 to promote a specific actin structure that associates with 
lower Yap activity 
 Previous result in Figure 4-4 identifies that NF2 is required for LKB1 to suppress Yap. 
We also established that an epithelial-like cell shape promoted by LKB1 is associated with Yap 
phosphorylation (Figure 4-1). Additionally, NF2 has an actin binding mechanism that is unique 
from conventional ERM proteins. NF2 binds to actin directly through its N-terminal domain or 
indirectly through βII-spectrin or fodrin (78). Therefore, we asked whether NF2 is required for 
LKB1 to promote the epithelial-like morphology.  
 HeLa cells with stable NF2 knockdown and LKB1 restoration were generated by co-
infection with lenti-viruses. In a similar process to Figure 4-2 C, LifeAct was used to visualize 
polymerized actin in these cells. Intriguingly, the knockdown of NF2 disrupts the epithelial-like 
shape that was induced by LKB1 expression (Figure 4-5 bottom right panel). Consistent with 
NF2’s role in suppressing Rac and Rho GTPase, cells with NF2 knockdown alone has more 
ruffles than non-targeted control shRNA infected cells (Figure 4-5 bottom left). Both in the 
presence and absence of LKB1, cells with NF2 knockdown have an increase in cell spreading. 
This spreading is a mesenchymal-like morphology that associated with higher Yap activity. 
However, the knockdown of NF2 did not completely prevent actin polymerization in LKB1 cells. 
Thus, further investigation is needed to confirm the requirement of this actin structure in the 
suppression of Yap. 
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Figure 4-5.  NF2 is required for LKB1 to promote an epithelial-like cell shape that is associated 
with lower Yap activity.   
HeLa cells were co-infected with lenti-virus carrying untagged LKB1or pCDH-Hygro vector control 
and NF2 targeted shRNA or non-target control similar to Figure 4-3 E. Upon selection for LKB1 using 
200 μg/ml hygromycin B, cells were transfected with LifeAct plasmid and actin structures were 
visualized as in Figure 4-2 C. Shown images were taken near the base of the cells, white arrows denote 
actin structures. 
Fluorescence images are representative.  
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4.4. DISCUSSION 
 
4.3.1. Actin structure reorganization might be an inside-out signaling event that links 
LKB1 expression to Yap suppression 
The inhibition of proliferation by cell-cell contacts is often thought of as an extrinsic 
event. Here, we presented evidence of this growth regulation as both outside-in and inside-out 
signaling. In the former case, outside stimuli are sensed by membrane associated proteins, 
conducted by scaffold proteins, and resulting in the regulation of transcriptional factors. In this 
study, the destruction of LKB1-induced structure by disrupting adherens junctions completely 
suppressed Yap phosphorylation, which associates with Yap inhibition. Since LKB1 promotes a 
rapid turn-over of Yap protein (Figure 3-4 D), the small decrease in total Yap level in LKB1 cells 
following EGTA treatment (observed in Figure 4-1 C) suggests that P-Yap is degraded in this 
process. Thus, it is likely that most of the Yap protein in LKB1-expressing cells is 
phosphorylated and sequestered at the junctions prior to its degradation. This result represents an 
outside-in mechanism where junction formation causes the rapid turn-over of Yap protein and 
growth arrest.  
On the other hand, LKB1 can promote an epithelial-like, cylindrical cell shape even in 
the complete absence of neighboring cells. This epithelial-like shape is associated with the 
formation of an actin cytoskeleton network and the relocalization of the tight junction protein 
occluden. This observation is very similar to Clevers’ work in intestinal cells, except the actin and 
occluden redistribution appear somewhat different (50). While LKB1-activated intestinal cells 
have actin caps that promote a brush border with ZO-1 surrounding these caps, HeLa cells have 
actin structures that promote an epithelial-like shape and occluden surrounding the cells. This 
morphological difference might be due to the original functions of these cells as intestinal or 
cervical lining, respectively. While more evidence is needed, at least in epithelial cell, it is 
unmistakable that LKB1 can promote a global effect on actin reorganization in a cell autonomous 
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fashion. This new actin structure in turn may direct Yap proteins to degradation sites and inhibit 
cell growth. Additionally, as junction-associated proteins like occluden are moved to the cell 
periphery, LKB1 expression may allow epithelial cells to efficiently form adhesions once cells 
come in contact with one another. The cell autonomous cytoskeletal structure and its 
susceptibility to form junctions represent a form of inside-out signaling that might further 
enhance the above outside-in regulation.  
 
4.3.2. The scaffold NF2 is required for LKB1 to reorganize actin structure and Yap 
 suppression  
In mammalian cells, a number of scaffolding proteins, such as 14-3-3, Amot family, 
Kibra, and NF2, have been reported to suppress Yap activity. These scaffolds are found close to 
the membrane and often interact with junctional proteins. For instance, 14-3-3 binds to both 
phosphorylated Yap and the junctional protein α-catenin in order to promote Yap sequestration to 
the adherens junction. Amot family members suppress Yap in similar fashion except the 
sequestration is to tight junctions and the actin cytoskeleton (136). Others proteins such as Kibra 
and NF2 have been shown to promote the activation of Mst-Lats in response to contact stimuli 
like E-caheren engagement. Other cell junction-associated proteins (PALS1, PATJ, MUPP1, and 
ZO2) that in turn associate with various Ser/Thr protein kinases also have been reported to 
interact with Yap or TAZ (reviewed in (27)). While our previous results suggest kinase(s) other 
than Lats also phosphorylate Yap, scaffolding proteins might be required to bring together 
inhibitory complexes for Yap suppression. 
Here, we established that the scaffold protein NF2 is required for LKB1 to cause the 
formation of a particular actin network associated with Yap inhibition (illustrated in Figure 4-6). 
Correspondingly, the knockdown of NF2 by two different shRNAs completely abolished LKB1’s 
effects on Yap downstream transcription and Yap phosphorylation. This result is particularly 
interesting since NF2’s ability to suppress cell growth and to regulate actin cytoskeleton depends 
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on its phosphorylation status (78). Under disadvantaged growth conditions such as low serum or 
high density, NF2 exists at the membrane in a “closed” conformation with its N- and C-terminus 
binding to each other. Phosphorylation of NF2 on Serine 518 or mutations found in NF2 patients 
disrupt this intramolecular interaction and “open” NF2 dissociates from the membrane. Unlike 
ERM proteins, NF2 “closed” conformation is regarded as the “active” conformation due to NF2 
functioning to suppress growth in this form. Meanwhile, “open” NF2 is redistributed from 
membrane to the cytosol (78, 80). A recent report suggested that “open” NF2 heterodimerizes 
with Ezrin although its function remains unclear (80). However, Rho (and not Rac or Cdc42) has 
been shown to translocate ERM proteins to the apical membrane and the actin protrusions (141). 
Since we observed that Rho specifically promotes Yap activity, it is possible that ERM proteins 
may also play a role in this actin organization. Furthermore, LKB1 restoration activates a number 
of kinases. It is possible that NF2 phosphorylation and de-phosphorylation allow dynamic 
movement of NF2 for cytoskeleton remodeling. This hypothesis is supported by the result that 
NF2 is required for LKB1 to form a distinct cylindrical cell shape as the result of F-actin 
formation (Figure 4-4). Interestingly, LKB1 can still promote some actin polymerization in the 
absence of NF2 but the overall structure is not the same as with NF2. Alternatively, Rho 
activation, which promotes actin stress fiber instead of cortical actin, increases Yap activity and 
does not completely reverse LKB1 suppression of Yap. Therefore, a specific actin structure 
promoted by LKB1 is associated low Yap activity. More investigation is needed to confirm 
whether a juxta-membrane actin structure is required for Yap phosphorylation and degradation to 
occur.  
An alternative hypothesis is that NF2 is required for intracellular trafficking of Yap and 
Yap inhibitory complexes to an appropriate location in growth permissive or growth suppressive 
conditions. In Drosophila, Yorkie (Yap ortholog) can be suppressed independent of 
phosphorylation via direct binding with Expanded, Warts (Lats), and Hippo (Mst) (142, 143). 
This direct association suppresses cell growth through Yorkie translocation to the cell membrane. 
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Interestingly, Expanded is a FERM-domain protein that complexes with NF2 (Merlin) and Kibra 
in both Drosophila and mammalian cells (35, 83, 143, 144). Thus, NF2 might play a part in 
trafficking complexes that travel along the actin cytoskeleton. Various reports highlighting NF2 
roles in vesicles trafficking (145, 146) and membrane lipid rafts association (147) support this 
possibility. While the exact mechanism of NF2 function requires more investigations, our results 
clearly define the role of NF2 scaffolding protein and the actin cytoskeleton in LKB1 regulation 
of Yap activity.  
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Figure 4-6.  The scaffolding protein NF2 and the actin cytoskeleton play an essential role in LKB1 
suppression of Yap activity.   
NF2 is required for LKB1 to promote an epithelial-like cell shape that is associated with Yap inhibition. 
This distinct morphology might be caused by the remodeling of actin cytoskeleton. While NF2 plays 
essential role in Yap suppression, it remains unclear how Yap phosphorylation and degradation occur. 
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CHAPTER 5. THE VIRAL ONCOGENE HPV-E6 PROMOTES YAP ACTIVITY 
LIKELY THROUGH RAP1B ACTIVATION 
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5.1. INTRODUCTION 
 
 The HPV-E6 gene from high-risk papilloma viruses is one of two viral oncogenes that 
causes the development of cervical cancer (2). E6 interacts with various cellular proteins and with 
an E3 ubiquitin ligase called E6AP. This event promotes ubiquitination of E6 target proteins and 
ultimately their degradation (86, 87) (illustrated in Figure 5-1 A). The major target of E6 is the 
tumor suppressor p53. Upon E6 expression, the degradation of p53 contributes to the inhibition of 
apoptosis and the reduction of downstream transcriptional targets of Notch required for 
differentiation (88, 89). Additionally, E6 from high risk HPV also enhances cancer malignancy 
by increasing cell spreading, adhesion, and promotes the thickening of the epidermis. However, 
the molecular signaling underlining these p53-independent functions of E6 remains elusive. 
Interestingly, E6 contains a PDZ domain-binding motif that is required for high-risk strain 31E6 
to promote keratinocytes growth on organotypic raft cultures (95). This motif allows E6 to bind 
and promote the degradation of a number of proteins containing PDZ domain(s) such as hScrib, 
hDlg, MAGI, MUPP1, PATJ, and PTPN3 (92). These PDZ-containing proteins are present in 
various polarity complexes and have crucial roles in cell junction formation and tissue structure. 
These observations encouraged us to examine a possible role of E6 in disruption of contact 
inhibition and Yap suppression. This chapter provides evidence that proliferation promoted by E6 
might be the result of increase Yap activity.  
 An unbiased screen for cellular targets of the high risk 16E6 resulted in the identification 
of E6-targeted protein 1 (E6TP1 also known as Sipa1L1). E6TP1 is a GAP that deactivates a 
small GTPase family of Ras-related proteins (Rap) (96, 97) (illustrated in Figure 5-1 B). The Rap 
family consists of several closely related members called Rap1A, Rap1B, Rap2A, Rap2B, and 
Rap2C with notable roles in junction formation, cell migration, and cancer invasiveness (102-
109). Importantly, Rap1 was shown as a crucial regulator of breast epithelial acinar structure in 
three dimensional culture. Activated Rap1-GTP promotes cell growth and suppression of Rap1 
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activity restores tissue polarity and induces lumen formation (114). Given E6’s ability to disrupt 
tissue structure and Yap suppression’s dependency on cell polarity, Rap1 was a prominent 
candidate for mediating E6 crosstalk with Yap. Here, we confirmed that Rap1 is activated by E6 
in keratinocytes. Intriguingly, Rap1B specifically promoted Yap activation downstream of E6; 
however, Rap1 functions independent of the cell differentiation status.  
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Figure 5-1.  HPV-E6 disrupts normal cellular processes and contributes to cancer development.  
A. E6 binds to E6-AP ubiquitin ligase and promotes the degradation of many tumor suppressors such as 
p53, PDZ-containing proteins, and hTERT inhibitor NFX1-91. These events contribute to a number of 
cancer promoting phenotypes including inhibition of differentiation.  
B. E6 promotes the degradation of E6TP1, a Rap1 GAP, which functions to deactivate a small 
molecular switch Rap1. This event is predicted to increase GTP bounded active Rap1.  
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5.2. RESULTS 
 
 5.2.1. Yap phosporylation level increases with keratinocyte differentiation 
 A major effect of high-risk E6 expression is the disruption of the keratinocytes 
differentiation process. This normal process is essential for the establishment of epithelial tissue 
structure through the increase of junctions and the reduction of cell proliferation (10). The 
inhibition of Yap is reported to play a key role in reducing the cell’s proliferative capacity (26, 
32). Therefore, we first confirmed Yap suppression by phosphorylation during normal 
differentiation. In tissue culture of primary keratinocytes, this differentiation process can be 
induced by bringing the calcium level in the media to 2.8 mM. Although NTERT are 
immortalized cells, they retain the capacity to differentiate (Figure 5-2 A). Cell lysates taken from 
NTERT keratinocytes at the denoted dates of differentiation were immunoblotted for P-Yap, total 
Yap, and GAPDH levels (Figure 5-2 B). Consistent with previous reports on epithelial tissue 
immuno-staining (26), Yap phosphorylation greatly increased with the differentiation of NTERT 
cells. Surprisingly, total Yap levels also mildly increase with differentiation, possibly through the 
stabilization of P-Yap at cell junctions.   
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Figure 5-2.  Yap phosporylation level increases with cellular differentiation. 
A. Non-cancerous NTERT keratinocyte are grown to high density and differentiated with 2.8 mM 
Calcium. 
B. Whole cell lysate (WCL) of NTERT at various day of differentiation is immunoblotted for YapS127 
phosphorylation and total Yap protein. The mean protein level from three experiments is indicated next 
to a representative blot. 
Error was computed as standard deviation of the mean.  
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5.2.2. HPV-E6 reduces Yap phosphorylation and promotes Yap nuclear localization  
 during keratinocyte differentiation 
The normal differentiation process promotes the inactivation of Yap (Figure 5-2 B). 
Additionally, a major cancer promoting effect of E6 is the inhibition of differentiation. Therefore, 
we investigated whether E6 promotes Yap activity during differentiation. NTERT keratinocytes 
were used to study the effect of E6 in isolation from other HPV proteins. A retro-viral system was 
used to stably express either the high-risk 16E6 (NTERT E6) or vector control (NTERT control). 
These stable cell lines were differentiated using calcium for the indicated numbers of day(s). 
Whole lysates from NTERT E6 or NTERT control cells were immunoblotted for the level of P-
Yap, total Yap protein, and β actin. Meanwhile, E6 activity was also confirmed via immunoblot 
of p53 and the differentiation marker involucrin. Consistent with the previous result, P-Yap levels 
greatly increase with differentiation. Interestingly, there was a significant increase of inactive P-
Yap in E6 expressing cells at every stage of differentiation (Figure 5-3 A). 
Yap phosphorylation is a reliable marker for the inhibition of Yap. However, a reduction 
of P-Yap level could be due to the disruption of cell junctions rather than a decrease in the rate of 
phosphorylation. Since E6 promotes the degradation of many junctional proteins (95), it was 
possible that E6 reduces P-Yap level through a reduction of Yap accumulation at the cell 
junctions. NTERT cells stably expressing E6 or vector control were induced to differentiate for 2 
days. Cytosol and nuclear enriched fractions from these cells were then immunoblotted for P-
Yap, total Yap, and p53 to measure the effect of E6. Additionally, GAPDH and Laminin A/C 
were used as markers for successful cytosolic and nucleic protein fractionation, respectively. 
Consistent with the above whole cell lysate blot (Figure 5-3 B), E6 expression reduces P-Yap 
level in the cytosol-enriched fraction. Significantly, E6 increases Yap nuclear localization, 
suggesting that E6 indeed promotes Yap activity during differentiation.  
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Figure 5-3.  HPV-E6 inhibits cell differentiation and promotes Yap activation. 
A. NTERT keratinocytes stably expressing E6 (NTERT E6) and vector control cells were differentiated 
for the indicated day(s). Lysate from these cells were immunoblotted for P-Yap, total Yap, involucrin - 
a marker of differentiation, p53, and GAPDH. 
B.  NTERT with E6 or control were differentiated for 2 days then subjected to nuclear fractionation and 
immunoblot as described in Figure 3-4 A/B. Representative blots are shown in left panel next to the 
quantification of average Yap protein from three independent experiments in the right panel. 
Errors and significance are as described in Figure 3-3. 
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5.2.3. Rap1 GTPase is activated by HPV-E6; however, Rap1 does not mediate E6 
differentiation inhibition 
Next, we focused on identifying a molecular pathway that mediates Yap activation by E6. 
A prominent candidate was Rap1, a member of the Ras family of small G proteins. Rap1 plays an 
important role in cell adhesion through its integrin and E-cadherin regulation (102-109). 
Additionally, Rap1 activation disrupts tissue structure and Rap1 suppression restores epithelial 
acinar architecture (114). Band’s lab reported that E6 induces Rap1 activation via the degradation 
of a Rap1 GAP named E6TP1. To confirm this result, previously described NTERT E6 or control 
cells were differentiated for the indicated days. The levels of Rap activation in these cells were 
measured by specific precipitation of the GTP-bound active Rap protein (Rap-GTP) from the cell 
lysates. Rap1-GTP was then measured by immunoblot using a Rap1 specific antibody. 2% input 
from whole cell lysate was also blotted as control for equal total Rap1 proteins. Consistent with 
E6 targeting Rap GAPs, E6 expression causes an increase in Rap1 activation regardless of 
differentiation stage. Surprisingly, Rap1-GTP amount increases with cell differentiation in both 
cell lines (Figure 5-4 A). Given that E6 inhibits differentiation, this increase in Rap1-GTP during 
normal differentiation suggests that Rap1 activation by E6 might serve a different function.  
 A major function of E6 is to inhibit the differentiation of keratinocytes from 
mesenchymal into epithelial cells. Meanwhile, the suppression of Yap and cell growth is 
associated with an epithelial phenotype. Although the above result suggested that Rap1 does not 
mediate E6-induced differentiation, we needed to rule out the deregulation of Rap1 in 
contributing to differentiation inhibition and consequently Yap suppression. Two different 
approaches were utilized: the overexpression of activated Rap1 mutants to mimic E6, and Rap1 
knockdown to reverse E6’s effect on cell differentiation. In the first approach, lenti-virus carrying 
two different constitutively active Rap1A mutants (63E and 28L) were utilized to infect NTERT 
keratinocytes alongside vector control lenti-virus. The 63E mutant is GTPase defective while the 
28L is a fast-cycling mutant. Both mutants have enhanced activation due to spending increased 
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time in the GTP-bound state. Although no drug selection was needed, the Rap1 protein was GFP 
tagged and infection efficiencies were confirmed by both fluorescence microscopy and 
immunoblot for GFP. Inhibition of calcium-induced differentiation was measured by 
immunoblotting cell lysates for the epithelial marker, involucrin. Surprisingly, compared to the 
large reduction of involucrin induced by 16-E6 (Figure 5-3 A), both activated Rap1 mutants had 
no effect on this differentiation marker (Figure 5-4 B). The second approach examined whether 
shRNA-targeted knockdown of both Rap1A and Rap1B could partially reverse E6’s suppression 
of differentiation. Two different shRNAs for Rap1B and one for Rap1A were used in various 
combinations to knock down both Rap1 proteins, which reduced the amount of Rap1-GTP, in 
NTERT E6 or control cell. Upon selection for stable knockdown, cells were differentiated and 
their lysates were immunoblotted for involucrin. Endogenous Rap1 was also monitored to 
confirm successful knockdown. Consistent with the Rap1 overexpression data, Rap1 knock down 
also did not affect the differentiation of either E6 or control cells (Figure 5-4 C). Altogether, these 
observations indicate that Rap1 activation by E6 does not affect keratinocyte differentiation. 
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Figure 5-4.  Rap1 is activated by E6; however, Rap1 does not effect keratinocyte differentiation. 
102 
 
A. Rap1 activation was measured by precipitation of the active GTP-bound form of Rap1 from NTERT 
E6 or control cells (described in Figure 5-3 A), using RalGDS RBD beads.  Bounded Rap-GTP proteins 
were immunoblotted, while 2% whole cell lysate input was blotted for total Rap1 protein. 
B. Using a lenti-virus system, two activated mutants of Rap1, 63E and 28L, were overexpressed in 
NTERT cells. Uninfected control, vector control, and cells stably expressing Rap1 mutants were then 
differentiated for the indicated days. Neither Rap1 mutant could mimic the effect of E6 to inhibit cell 
differentiation as measured by immunoblot of the epithelial marker, involucrin. Asterisk indicates non-
specific band.  
C. Control or E6-expressing NTERT cells were infected with lenti-virus expressing shRNA against 
Rap1. Lysates from these cells following the indicated days of differentiation were immunoblotted for 
involucrin marker, endogenous Rap1, and GAPDH.  
Figure A, B, and C are the representatives of two experiments. 
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5.2.4. Rap1B likely mediates Yap activation by HPV-E6 independent of cell 
differentiation 
 Although changes in Rap1 activity did not disrupt keratinocyte differentiation, Rap1 
over-activation has been shown to cause the destruction of tissue architecture and leads to tumor 
progression (114). Since E6 expression promotes both Yap nuclear localization (Figure 5-3) and 
Rap1 activation (Figure 5-4 A), we were interested in whether Rap1 activation by E6 increases 
Yap activity independent of cell differentiation. In order to study Rap1’s effect in the presence of 
E6, we utilized HeLa cells that already express high-risk 18E6 and 18E7 proteins. Using the 
TEAD reporter assay described in Figure 3-3, Yap downstream activity was measured following 
the overexpression of closely related Rap family members Rap1A, Rap1B, Rap2A, and Rap2B. 
Interestingly, while Rap2 and Rap1A expressions mildly affected Yap activity in comparison to 
vector control, Rap1B specifically promoted Yap activation (Figure 5-5 A). 
 In order to confirm the ability of Rap1B to promote Yap activity, two different shRNA 
targeting Rap1B and one targeting Rap1A were transfected to HeLa cells together with TEAD 
activity reporters. Consistent with overexpress data, the knockdown of Rap1A had only a small 
effect while the knockdown of Rap1B vastly reduced TEAD transcriptional activity (Figure 5-5 
B). Alternatively, we overexpressed two Rap GAPs (Rap1gap and E6TP1) that indiscriminately 
deactivate Rap proteins and two Rap GEFs (EPAC and C3G) that activate Rap. Similar to the 
knockdown of Rap1 proteins, the expression of GAP reduced Yap activity. Conversely, the 
expression of GEF promoted Yap downstream activity (Figure 5-5 C). Thus, although Rap1 does 
not mediate E6’s inhibition of differentiation, these data suggest it is possible for Rap1B to 
promote Yap activity in HPV-positive cells. 
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Figure 5-5.  Rap1B specifically promotes Yap activity and might mediate Yap activation by HPV-
E6. 
A. HeLa cells (that are HPV18-positive), were transfected with TEAD reporter plasmids and plasmids 
expressing the indicated Rap family members or vector control. Yap activity was inferred from 
luciferase signal as described in Figure 3-3. 
B. Similarly HeLa cells were transfected with plasmids containing shRNA targeting the indicated Rap1 
member and Yap downstream transcriptional activity was examined. 
C. Consistently, overexpression of Rap1 GAPs increased while and Rap GEFs decreased TEAD 
signals. 
Figure A and B are representative of two independent experiments each performed in triplicate. Errors 
and significance are as described in Figure 3-3. 
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5.3. DISCUSSION 
 
5.3.1. HPV-E6 promotes growth during differentiation likely through Rap1B-Yap 
 activation   
The viral oncoproteins E6 and E7 are the causal factors of cervical cancer development. 
The current perspective is that E7 promotes cell growth while E6 prevents cell death and 
differentiation (1, 2, 148). However, E6 has been shown to promote cell growth in some cases 
(90, 95, 149) prompting us to examine the effects of E6 on the progrowth transcription factor 
Yap. The expression of E6 in NTERT keratinocytes reduces Yap phosphorylation and increases 
nuclear Yap levels throughout the differentiation process. Since calcium-induced differentiation 
of keratinocyte suppresses Yap, the question remains whether E6 promotes growth or E6 prevents 
growth arrest through its disruption of differentiation. Here, we found evidence that E6 promotion 
of Yap activity is associated with the activation of the Rap1 small GTPase. The expression of 
high risk HPV-16E6 in non-cancerous keratinocytes strongly increases Rap1-GTP levels at all 
stages of differentiation. Additionally, in HeLa cells with E6 expression, the expression of Rap1 
(but not Rap2) increased Yap downstream activity. Similarly, the knockdown of Rap1 decreased 
TEAD activity. Rap1B knockdown was more effective at reducing TEAD activity than Rap1A 
knockdown. Therefore our data suggest the possibility that HPV-E6 activates Rap1B which in 
turn may promotes Yap activity. The observation that Rap1 promotes Yap activity without 
effecting cell differentiation suggests that E6 regulation of Yap is growth promoting and not a 
result of growth arrest. However, the confirmation of this result will require experiments examine 
keratinocyte growth in 3D raft culture.   
It is worth noting that E6 harbors a PDZ-binding motif, which might play a crucial role in 
E6’s ability to cause the thickening of the epidermis (95). This PDZ-binding motif enables E6 to 
target a number of PDZ domain-containing polarity-associated proteins for degradation. 
Interestingly, at least two E6 targets, MUPP1 and PATJ have been shown to interact with Yap. 
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On the other hand, both Yap and Taz contain a PDZ-binding motif at their C terminus. At least 
for Yap2, this PDZ-binding motif is required for Yap binding to zonula occluden 2 (ZO-2) and 
Yap shuttling to the nucleus (39, 150). Thus, one may speculate that E6 releases Yap from 
membrane proteins through the degradation and disruption of polarity-associated complexes. 
Furthermore, E6TP1 and several other Rap1 GAPs all have a highly conserved (80 to 90% 
identity) PDZ domain. Interestingly, a non-synonymous amino acid polymorphism, A739T, in the 
PDZ domain of a Rap1 GAP called Sipa1 (Signal-induced proliferation-associated protein 1, also 
known as Spa-1) causes a drastic increase in the metastatic potential of breast cancer (151). Sipa1 
is also shown to regulate the trafficking to the membrane of a protein channel Aquaporin 2 (152). 
Consistently, a number of studies support the role of Rap1 in protein-trafficking regulation. For 
instance, Rap1 regulates the endocytic recycling of E-cadherin to promote stem cell renewal 
(153). Alternatively, Rap1 cooperates with p38 MAPK and MAPK kinase 3/6 to couple receptor 
endocytosis with long term depression of neuronal synapses (154). Therefore, it is possible that 
Rap1 activation by E6 promotes the shuttling of Yap to the nucleus for the transcription of 
proliferative genes.  
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Figure 5-6.  HPV-E6 likely promotes keratinocyte growth through Rap1-Yap activation.   
The viral oncogene E6 promotes Yap activity, which otherwise is suppressed by cell differentiation. E6 
also causes Rap1 activation. Since Rap1B specifically and potently increase Yap downstream 
transcription and Rap1 does not mediate the effect of E6 on differentiation, it is likely that E6 increases 
Yap function through Rap1. 
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5.3.2. Possible distinct functions of various Rap family members 
Rap1A, Rap1B, Rap2A, Rap2B, and Rap2C are members of the Ras superfamily. These 
Rap proteins are encoded by five different genes which most studies have shown to be largely 
redundant. Interestingly, our data indicates that these Rap family members may have distinct 
effects on Yap activity. The general perspective is that Rap family members are differentially 
expressed in various cell types during different stages of development. Rap1 and Rap2 share a 
number of redundant functions. Rap1A was first discovered as a Ras antagonist which competes 
with the Ras-binding domain of Raf (c-Raf) preventing Ras from activating it. Thus Rap was 
found to suppress cancer growth through interference with Ras-signaling. Later, Rap1 was found 
to promote proliferation in cells that contain B-Raf through the ERK mitogen-activated protein 
kinases pathway (100). Additionally, Rap2 may activate JNK through MAP4K4 to promote cell 
growth (101). Therefore, the availability of Rap downstream effectors dictates their downstream 
effects. This fact underscores the tissue specificity of Rap family members and the different roles 
these family members may play in different contexts. Like Ras, Rap shuttles between active GTP-
bound and inactive GDP-bound states, upon activation by GEFs and deactivation by GAPs (99). 
Rap1 and Rap2 exhibit 60% sequence identity and these Rap family members share a number of 
GEFs and GAPs. However, these GEFs and GAPs have different cellular localization and 
preferential activity toward various Rap family members. Thus, Rap members are regulated via 
specific expression in each cell type as well as via intracellular localization. The diversity of Rap 
family members and regulatory proteins allow Rap to intricately control many processes in a cell 
and tissue specific manner. Given reported roles of Rap and its regulators in acinar polarity (114), 
gastrulation development (155), and angiogenesis (156, 157), it is likely that different Rap 
members have evolved to accommodate development of various organs as well as tissue 
homeostasis in multicellular organisms.     
Here, we found that Rap1A and Rap1B activate Yap while Rap2A and 2B mildly 
represses Yap activity. Thus Rap1 and Rap2 might differentially regulate cell growth even though 
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both Rap1 and Rap2 have been shown to promote cell adhesion (105, 109, 135, 158). This could 
explain the “bad Rap/good Rap” effects where increased Rap activity was reported to both 
negatively and positively influence cancer progression depending on the particular circumstance 
(99). Additionally, Rap2A was recently shown to mediate brush border formation in response to 
LKB1 activation in intestinal cells (135). In this report, LKB1 promotes recruitment of PDZGEF 
to the cell membrane. This event specifically increased Rap2A-GTP (and not other Rap members) 
and triggered a cascade composed of the Rap2A effector called TRAF2 and NCK interacting 
kinase (TNIK), the Mst4 kinase, and Ezrin (135). Thus, it is possible that the loss of LKB1 
decreases Rap2-GTP level while the expression of E6 increases Rap1 activity leading to cervical 
cancer. Our result of Rap1 promoting and Rap2 repressing Yap activity would be consistent with 
this idea.  
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CHAPTER 6. CONCLUDING REMARKS 
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6.1. FUTURE STUDIES 
  
 6.1.1. The dilemma of growth and death  
 At the turn of this century, Yap was identified as a proapoptotic factor in Cos7 (monkey 
kidney fibroblast) and MCF7 (human breast cancer) cell lines (38). Several reports subsequently 
showed that nuclear Yap interacted with the transcription factor p73 (p53 homolog) and 
promyelocytic leukemia protein (PML) (38, 159, 160) to promote the expression of apoptotic 
proteins such as Bax, p53AIP, and PUMA. This activation of Yap was in response to apoptotic 
signals by the stimulation of Fas ligand receptor. However, a shift away from the focus on Yap’s 
pro-apoptotic function(s) resulted from overwhelming Drosophila and mouse genetic data. These 
studies confirmed the role of Yap (Yki in flies) in promoting cell proliferation. However, we 
observed that Yap activation also causes cellular toxicity. The knockdown of Yap suppressors 
such as NF2, LKB1, and Lats1/2 promotes cell death even though Yap downstream transcription 
of proliferative genes is greatly increased. Indeed, non-cancerous keratinocytes with NF2 
knockdown survive less than a week. Strangely, although the knockdown of LKB1 increased 
growth readouts such as cell size and CTGF gene expression, cells eventually died. More 
interestingly, the stable knockdown of Lats1 or Lats2 by shRNAs (not transiently expressed 
siRNAs) lead to cell death of both cancerous HeLa cells and non-cancerous keratinocytes. It is 
worth noting that similar to Yap, the deregulation of other oncogenes like c-myc (161) and ras 
(162) also causes cell death under numerous conditions. For instance, fibroblasts with c-myc 
ectopic expression undergo apoptosis without the presence of survival factors in culture media 
(163). Similarly, a review by Maltese outlined various pathways that mediate Ras-induced cell 
death including the regulation of Bcl proteins via RASSF1A, ERK, Rac, and p53 downstream 
signals (162). Although many controversies surround oncoprotein-induced apoptosis, the most 
widely held view is that proliferation sensitizes cell to apoptosis and the availability of co-factors 
and survival signals allow cancer cells to thrive. Thus far, there are few factors like p73 and PML 
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that influence Yap pro-apoptotic function. Deciphering the cellular events/factors which 
determine the different outcomes of Yap/Taz activation is an intriguing source of ongoing 
investigation with important implications in cancer development and treatment.  
 
 6.1.2. The regulation of Taz 
 In mammalian cells, Yap and Taz are often mentioned as two identical orthologs of the 
Drosophila Yorkie. This grouping of Yap and Taz proteins is deemed acceptable due to their 
redundant functions as transcription co-activators. For instance, both Yap and Taz interact with 
transcription factors such as TEAD, RUNX, p73, PAX, TTF-1 (also known as NKX2.1), TBX5 
(also known as NKX2.5), PPAR, and SMAD family (27). Additionally, YAP and Taz are 
suppressed by phosphorylation and cytosolic retention via interactions with 14-3-3 proteins in 
growth disadvantaged conditions. The fact that Yap/Taz double knockout mice cease to develop 
beyond the 16-32 cell stage further confirms their roles in cell proliferation. However, the 
phenotypes of the individual gene knockouts in mice indicate there may be subtle differences in 
their functions. For example, mice with Yap deletion will not develop past E8.5, while Taz 
depletion causes lung and kidney defects that usually lead to embryonic lethality (27). A recent 
study examining the effect of stress fibers, induced by cell spreading, on Yap/Taz localization 
showed that stress fiber disruption preferentially affects the phosphorylation and stability of Taz 
protein more than Yap (41). Thus it is possible that these homologous proteins are differentially 
regulated. 
 Our preliminary work on Taz showed that Taz is regulated in a similar manner to Yap. 
As observed with Yap, E6 expression and NF2 knockdown both significantly increase 
endogenous Taz levels (Figure 6-1 A and B). This result is consistent with the previously 
observed increase in the activity of TEAD transcription factor, which binds to both Yap and Taz. 
Meanwhile, LKB1 expression did not affect Taz protein expression levels (Figure 6-1 B). 
However, this steady Taz level with LKB1 expression might represent Taz sequestration at the 
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junction. Thus measurement of the Taz phosphorylation sites Serine 89 and Serine 311, Taz 
accumulation in the nuclear fraction, or Taz turn-over would be needed to confirm whether LKB1 
does not affect Taz. Most interestingly, AMPK activation via glucose starvation in the presence 
of LKB1 decreases Taz level (Figure 6-1 A). This result is surprising since we did not see any 
change in Yap phosphorylation with AMPK activation using this same method with or without 
LKB1 (Figure 3-8 C). AMPK regulation of Taz stability suggests that LKB1-induced growth 
suppression is mediated by both Yap and Taz through distinct regulators. However, no conclusion 
about Taz regulation can be made from these limited findings.  
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Figure 6-1.  The regulation of Taz by NF2, E6, and possibly AMPK.   
A. Keratinocytes stably expressing HPV-16E6 or control (as described in Figure 5-3) were incubated in 
glucose deficient media for 2 hours. WCL from the treated and control were immunoblotted for Taz, P-
Yap, and total Yap level. P-ACC and total ACC were also measured as control for the activation of 
AMPK by glucose starvation. LKB1 and GAPDH were blotted to ensure equal loading.  
B. HeLa cells stably expressing LKB1 in combination with shRNA targeting NF2 or control (as 
described in Figure 4-3 C) were plated out for 2 days. Cell lysates were immunoblotted for Taz and Yap 
level as in part A. NF2 level were also measured to ensure adequate knockdown. 
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 6.1.3. The mechanism of how NF2 suppresses Yap 
 The scaffolding protein NF2 (Merlin) suppresses cell growth through multiple signaling 
pathways. The best characterized signaling event downstream of NF2 is the inactivation of Rac1-
PAK which subsequently leads to activation of the MAPK pathway. This inhibition of the Rac1-
PAK axis is mediated by a tight-junction-associated protein complex comprising of Amot, Patj, 
and Pals1. In growth suppressive condition, NF2 binds to this complex and releases Rich1, which 
is a GAP that deactivates Rac1 (61, 72, 134). Additionally, NF2 mediates contact inhibition of 
cell growth through the Hippo/Yap pathway. NF2 expression activates the Hippo kinases Mst and 
Lats (61-63) and could suppress Yap independent of Mst or Lats (32, 43). While Yap activity was 
not strongly affected by Rac1, PAK, or Amot in our system, reports regarding Amot inhibition of 
Yap (136) and Pals1-Patj interaction with Yap (27) in different cellular systems suggest a 
possible cross-regulation between these seemingly parallel pathways.   
 Since LKB1 expression promotes a drastic change in the actin cytoskeleton structure and 
NF2 is required for epithelial-like cell shape, we hypothesize that ERM proteins might mediate 
LKB1 suppression of Yap. This idea is supported by ERM proteins key role in actin regulation. 
Furthermore, Ezrin (an ERM protein) works downstream of LKB1 to promote formation of the 
brush borders of intestinal epithelial cells. Additionally, when NF2 is phosphorylated and 
assumes an “open” conformation, it forms heterodimers with ERM proteins. Since LKB1 
restoration activates a number of kinases, it is possible that NF2 phosphorylation affects NF2-
ERM proteins heterodimerization. Therefore, future investigation examining the impact of 
phospho-deficient S418A and phospho-mimic S418D mutants of NF2 (Ref) might implicate NF2 
phosphorylation in mediating effects of LKB1. Cellular phenotypes such as Yap dependent 
transcription and cell growth could be measured in combination with NF2 mutants. Alternatively, 
NF2 and Yap proteins’ subcellular localization with LKB1 expression may help answer whether 
NF2 functions in a juxta-membrane complex that suppresses Yap. 
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 6.1.4. The synergistic effect between E6 expression and LKB1 loss 
 An equally intriguing question not addressed in this dissertation is possible synergism 
between LKB1 loss and HPV infection in cervical cancer malignancy. The evidence for this 
synergistic effect is that patients with LKB1-deficient cervical cancer have a median survival of 
13 months while others with LKB1-wild type tumors survive more than 100 months (7). 
Additionally, Peutz-Jeghers patients with LKB1 loss suffer a >15 times risk of developing 
malignant epithelial cancers at various sites (164). We speculate three possible consequences of 
combining LKB1 deletion with E6 incorporation. Firstly, E6 expression prevents cell death that is 
induced by the loss of LKB1 as discussed above. Thus keratinocytes harboring somatic mutations 
in LKB1 or its downstream mediator of Yap suppression could survive proliferative-stress and 
continue to growth. Secondly, LKB1 and E6 might affect different opposing growth regulators. 
For instance, LKB1 promotes activation of Rap2 (135) which has negative influence on TEAD 
gene transcription (Figure 5-5 A), while E6 activates Rap1 which increases Yap function (Figure 
5-5 B). Alternatively, LKB1 depletion and E6 expression may differentially increase Yap or Taz 
levels (Figure 6-1). A third possibility is that epithelial structure disruption, as a result of LKB1 
deficiency, allows HPV-infected cells to invade and metastasize. This hypothesis is in line with 
our previous discussion that LKB1 may enhance cell adhesion through the redistribution of 
junction proteins. This idea is also supported by numerous reports that describe LKB1’s role in 
suppressing the metastasis and invasiveness of lung epithelial cancers, adenocarcinomas, 
squamous cell carcinomas, prostate epithelium, and endometrial epithelium (49, 117, 165). Future 
investigations using an E6/E7 transgenic mouse that has been crossed to enable epithelial tissue 
specific knockout of LKB1 might provide mechanistic insights into the development of malignant 
cervical cancer. Understanding the synergy between HPV oncoproteins and LKB1 loss may lead 
to possible treatments for these highly metastatic cervical carcinomas.  
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6.2. CONCLUSION 
 
 In summary, I have identified two pathways, LKB1-NF2-Yap and E6-Rap1-Yap that 
uncover how the structure of a cell directly influences its gene expression and proliferation. These 
pathways both have crucial implications in the development of cervical cancer. LKB1 and NF2 
induce actin cytoskeleton organization and cell cohesion, which in turn suppress both Yap 
activity and cell growth. Meanwhile, the viral oncogene HPV-E6 activates the Rap1 GTPase 
leading to Yap nuclear localization and increased transcription of proliferative genes. These 
results are consistent with clinical data indicating poor prognosis of patients with combined 
somatic mutations in LKB1 plus E6 overexpression (7). Therefore, future investigations 
examining possible synergism between these events may provide either a diagnostic tool or new 
therapy for malignant cases of cervical cancer. 
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APPENDIX – NUCLEOTIDE SEQUENCES 
 
CLONING PRIMERS 
LKB1 PCR amplification with EcoRI/NotI overhang 
Forward 5'- GAATTC atgga ggtggtggac ccgcag  
Reverse 5'- GCGGCCGC TCA CTG CTG CTT GCA GGC CGA C  
E6TP1 (two-steps cloning with internal HindIII) 
Forward 5'- atat GGCGCGCC AT GAC CAG CTT GAA ACG GTC AC  
Reverse 5'- AGG CGA ATT CAA GCT TTC TCC AGA TGT TCC CTG 
KIAA1389 (two-steps cloning with internal XhoI) 
Forward 5’- cact GGCGCGCC gt cccttttggg ttccctgaat  
Reverse 5'- tagc CTCGAG AGA GCG CAA TCC GCC T  
hSIPA (two-steps cloning with internal StuI-methylated) 
Forward 5’- gctaGGATCC CCC ATG TGG GCC GGC 
Reverse 5’- tagc GAATTC CCA CCC AGG CCT AGC  
 
POLYLINKERS OF MULTIPLE CLONING SITES 
v309-linker with the following restriction sites 
AscI, BamHI, XhoI, EcoRI, NheI, SmaI/XmaI, PacI  
GGCGCGCCGGATCCCTCGAGGAATTCGCTAGCCCCGGGTTAATTAA 
v309-L2 and v309-L3 are the same modified polylinker added HindIII site with second and third 
reading frame, respectively.  
v309-L2 
GGCGCGCCAGGATCCAAGCTTCTCGAGGAATTCGCTAGCCCCGGGTTAATTAA 
v309-L3 
GGCGCGCCAAGGATCCCTCGAGAAGCTTGAATTCGCTAGCCCCGGGTTAATTAA 
pCDH-puro and hygro with the following restriction sites 
NotI, AscI, BamHI, XbaI, EcorI, PacI  
GCG GCC GCG GCG CGC CGG ATC CTC TAG AGA ATT CTT AAT TAA  
 
RT-PCR PRIMERS AND PROBES 
CTGF NM_001901.2 
Forward 5'- agctgacctggaagagaacatt 
Reverse 5'- gctcggtatgtcttcatgctg 
Probe #71 universal probe library 
HDM2 NM_002392.3 
Forward 5'- tctgatagtatttccctttcctttg 
Reverse 5'- tgttcacttacaccagcatcaa 
Probe #21 universal probe library 
ACTIN (note that actin is not a good normalizing standard in many cases) 
Multiplex Actin probe – HEX dye 
GAPDH NM_002046.3 (standard) 
Forward 5'- agccacatcgctcagacac 
Reverse 5'- gcccaatacgaccaaatcc 
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Probe #60 universal probe library  
RPLP0 NM_053275.3 (standard) 
Forward 5'- tctacaaccctgaagtgcttgat 
Reverse 5'- caatctgcagacagacactgg 
Probe #6 universal probe library 
 
shRNA SEQUENCES 
Non-targeted scramble of luciferase (166) 
CCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGCGACTTAACCTTAGG 
Targeting LKB1 
shLKB1#1 or 408 (TRCN0000000408) 
CCGGGCCAACGTGAAGAAGGAAATTCTCGAGAATTTCCTTCTTCACGTTGGCTTTTT 
409 (TRCN0000000409) 
CCGGGATCCTCAAGAAGAAGAAGTTCTCGAGAACTTCTTCTTCTTGAGGATCTTTTT 
shLKB1#2 or 411 (TRCN0000000411) 
CCGGCATCTACACTCAGGACTTCACCTCGAGGTGAAGTCCTGAGTGTAGATGTTTTT 
Targeting LATS 
shLATS 1 (TRCN0000001777) 
CCGGCACGGCAAGATAGCATGGATTCTCGAGAATCCATGCTATCTTGCCGTGTTTTT 
shLATS 2 (TRCN0000000880)  
CCGGCCGTCGATTACTTCACTTGAACTCGAGTTCAAGTGAAGTAATCGACGGTTTTT 
Targeting NF2 
shNF2 #1 or 38 (TRCN0000018338) 
CCGGTAGTTCTCTGACCTGAGTCTTCTCGAGAAGACTCAGGTCAGAGAACTATTTTTG 
shNF2 #2 or 74 (TRCN0000039974) 
CCGGGCTCTGGATATTCTGCACAATCTCGAGATTGTGCAGAATATCCAGAGCTTTTTG 
shNF2 #77 (TRCN0000039977) 
CCGGCGACTTCAAAGATACTGACATCTCGAGATGTCAGTATCTTTGAAGTCGTTTTTG 
Targeting RAP1 
mouse shRNA Rap1A #4 (TRCN0000055269) 
CCGGGCTCAGTCTACGTTTAATGATCTCGAGATCATTAAACGTAGACTGAGCTTTTTG 
mouse shRNA Rap1A #5 (TRCN0000055272) 
CCGGCGGGTAGTTGGCAAAGAACAACTCGAGTTGTTCTTTGCCAACTACCCGTTTTTG 
mouse shRNA Rap1B #1 (TRCN0000102735) 
CCGGCGCTTTGATTAACACAGCTATCTCGAGATAGCTGTGTTAATCAAAGCGTTTTTG 
mouse shRNA Rap1B #2 (TRCN0000102736) 
CCGGCCTACGATAGAAGATTCTTATCTCGAGATAAGAATCTTCTATCGTAGGTTTTTG 
mouse shRNA Rap1B #5 (TRCN0000102739) 
CCGGCAGTCGACATTTAACGACTTACTCGAGTAAGTCGTTAAATGTCGACTGTTTTTG 
human shRNA Rap1A #4 (TRCN0000029787) 
CCGGGCTCTGACAGTTCAGTTTGTTCTCGAGAACAAACTGAACTGTCAGAGCTTTTT 
mouse shRNA Rap1B #1 (TRCN0000029174) 
CCGGCCAATGATTCTTGTTGGTAATCTCGAGATTACCAACAAGAATCATTGGTTTTT 
mouse shRNA Rap1B #4 (TRCN0000029177) 
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CCGGGCACAACAGTGTATGCTTGAACTCGAGTTCAAGCATACACTGTTGTGCTTTTT 
 
siRNA SEQUENCES 
Non-targeted si control Dharmaco ON-TARGET Plus  
D-001810-10 sequence not available 
siLATS1 – siGENOME SMART pool M-003865, includes these sequences 
D-003865-04 GAACGAUGCCAGCGAAGGU 
D-003865-03 GAUCGGUGCCUUUGGAGAA 
D-003865-02 GAAAGAGUCUAAUUACAAC 
D-003865-01 GUUCGGACCUUAUCAGAAA 
siLATS2 - siGENOME SMART pool M-004632, includes these three sequences 
D-004632-04 GAUAAAGACACUAGGAAUA  
D-004632-03 GAAAUCAAGUCGCUCAUGU 
D-004632-02 GCAAGUCACUCUGCUAAUU 
D-004632-01 GAACCAAACUCUCAAACAA 
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